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Background: Magnesium sulphate, administered by the intravenous (i.v.) or inhaled (nebulised) route, has
been proposed as a treatment for adults with acute severe asthma. Existing trials show mixed results and
uncertain evidence of benefit.
Objectives: We aimed to determine whether i.v. or nebulised magnesium sulphate improves symptoms of
breathlessness and reduces the need for hospital admission in adults with acute
severe asthma.
Design: Multicentre, double-blind, placebo-controlled, three-arm, randomised trial.
Setting: The emergency departments of 34 acute hospitals in the UK.
Participants: We recruited 1109 adults (age > 16 years) with acute severe asthma [peak expiratory flow
rate (PEFR) < 50% of best/predicted, respiratory rate > 25 breaths per minute, heart rate > 110 beats per
minute or inability to complete sentences in one breath]. Patients with life-threatening features or a
contraindication to either nebulised or intravenous magnesium sulphate were excluded.
Interventions: Participants were randomly allocated to i.v. magnesium sulphate (2 g over 20 minutes) or
nebulised magnesium sulphate (3 × 500mg over 1 hour) or standard therapy alone.
Main outcome measures: The primary outcome was the proportion of patients admitted to hospital
(either after emergency department treatment or at any time over the subsequent 7 days) and
breathlessness measured on a 100-mm visual analogue scale (VAS) over 2 hours after initiation
of treatment.
Results: We randomised 406 patients to i.v. magnesium sulphate, 339 to nebulised magnesium sulphate
and 364 to placebo. Hospital admission was recorded for 394, 332 and 358 patients, respectively, and
VAS breathlessness for 357, 296 and 323 patients respectively. Mean age was 36.1 years and 763 out of
1084 (70%) patients were female. Intravenous magnesium sulphate was associated with an odds ratio
(OR) of 0.73 [95% confidence interval (CI) 0.51 to 1.04; p = 0.083] for hospital admission, an improvement
in VAS breathlessness that was 2.6 mm (95% CI –1.6 to 6.8 mm; p = 0.231) greater than that associated
with placebo and an improvement in PEFR that was 2.4 l/minute (95% CI –8.8 to 13.6 l/minute; p = 0.680)
greater than that associated with placebo. Nebulised magnesium sulphate was associated with an OR ofv
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ABSTRACT
vi0.96 (95% CI 0.65 to 1.40; p = 0.819) for hospital admission, an improvement in VAS breathlessness that
was 2.6 mm (95% CI –1.8 mm to 7.0 mm; p = 0.253) less than that associated with placebo and an
improvement in PEFR that was 2.6 l/minute (95% CI –9.2 to 14.5 l/minute; p = 0.644) less than that
associated with placebo. There were no significant differences between i.v. or nebulised magnesium
sulphate and placebo for any other outcomes. The number (%) of patients reporting any side effect was
61 (15.5%) in the i.v. group, 52 (15.7%) in the nebuliser group and 36 (10.1%) in the placebo group.
The ORs for suffering any side effect were 1.68 (95% CI 1.07 to 2.63; p = 0.025) for i.v. compared with
placebo and 1.67 (95% CI 1.05 to 2.66; p = 0.031) for nebuliser compared with placebo.
Conclusions: We were unable to demonstrate a clinically worthwhile benefit from magnesium sulphate in
acute severe asthma. There was some weak evidence of an effect of i.v. magnesium sulphate on hospital
admission, but no evidence of an effect on VAS breathlessness or PEFR compared with placebo. We found
no evidence that nebulised magnesium sulphate was more effective than placebo.
Trial registration: Current Controlled Trials ISRCTN04417063.
Source of funding: This project was funded by the NIHR Health Technology Assessment programme and
will be published in full in Health Technology Assessment; Vol. 18, No. 22. See the NIHR Journals Library
programme website for further project information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Magnesium sulphate, administered by the intravenous (i.v.) or inhaled (nebulised) route, has been
proposed as a treatment for acute severe asthma. Meta-analysis of 11 trials (1018 patients) of i.v.
magnesium sulphate in adults with acute asthma showed evidence of an effect on respiratory function
[standardised mean difference (SMD) 0.35, 95% confidence interval (CI) 0.06 to 0.64; p = 0.02] but not
hospital admission [relative risk (RR) 0.85, 95% CI 0.68 to 1.06; p = 0.14]. Meta-analysis of seven trials
(430 patients) of nebulised magnesium sulphate in adults with acute asthma showed weak evidence of
improved respiratory function (SMD 0.17, 95% CI –0.02 to 0.36; p = 0.09) but not hospital admission
(RR 0.87, 95% CI 0.70 to 1.08; p = 0.22). No previous trials have directly compared i.v. with nebulised
magnesium sulphate. It is not clear whether changes in measures of respiratory function are associated
with important changes in patient management or a clinically meaningful improvement in symptoms.Objectives
We aimed to measure the effectiveness and cost-effectiveness of i.v. and nebulised magnesium sulphate in
acute severe asthma. Our specific objectives were to determine whether (1) i.v. or nebulised magnesium
sulphate reduces the proportion of patients who require admission at initial presentation or during the
following week and (2) i.v. or nebulised magnesium sulphate improves patients’ assessment of their
breathlessness over 2 hours after initiation of treatment. We also measured the effect of i.v. or nebulised
magnesium sulphate on length of hospital stay; use of the intensive care unit (ICU) or high-dependency
unit (HDU); mortality; adverse events and use of respiratory support; change in peak expiratory flow rate
(PEFR) and physiological variables after initial treatment; health utility; patient satisfaction with care; use of
health and social services over the following month; time taken off work; and health and social care costs.Methods
We undertook a multicentre, double-blind, placebo-controlled, three-arm, randomised trial in
34 emergency departments (EDs) in the UK. Adults (age > 16 years) attending the ED with acute severe
asthma were eligible for recruitment (i.e. acute asthma with either PEFR < 50% of best or predicted,
respiratory rate > 25 breaths per minute, heart rate > 110 beats per minute or inability to complete
sentences in one breath). We excluded patients who had life-threatening features, a contraindication to
either nebulised or i.v. magnesium sulphate (pregnancy, hepatic or renal failure, heart block or known
hypermagnesaemia), those unable to provide written or oral consent and previous participants in the
3Mg trial. We amended the protocol during the trial to also exclude those patients who had received
magnesium sulphate in the 24 hours prior to recruitment. Written or verbal consent was sought from
all participants.
Consented participants were randomised to either (1) i.v. magnesium sulphate, 8 mmol (2 g) in 100 ml
normal saline given over 20 minutes and three 7.5-ml vials of 0.9% saline nebulised at 20-minutes
intervals; or (2) i.v. normal saline, 100 ml given over 20 minutes and three 7.5-ml vials of 2 mmol (500 mg)
magnesium sulphate nebulised at 20-minute intervals; or (3) i.v. normal saline, 100 ml given over
20 minutes and three 7.5-ml vials of 0.9% saline nebulised at 20-minute intervals.xv
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SCIENTIFIC SUMMARY
xviStandard therapy was provided in accordance with guidelines from the British Thoracic Society and Scottish
Intercollegiate Guidelines Network (SIGN) and consisted of oxygen, nebulised salbutamol, nebulised
ipratropium bromide and oral prednisolone administered during recruitment, followed by up to 5mg of
salbutamol added to each trial nebuliser. Other treatments were given at the discretion of the clinician.
Two primary outcomes were specified: (1) admission to hospital, either after ED treatment or at any time
over the subsequent week, and (2) visual analogue scale (VAS) for breathlessness over 2 hours after
initiation of treatment. Secondary outcomes included mortality; adverse events; use of ventilation or
respiratory support; length of hospital stay; use of ICU or HDU; change in PEFR and physiological variables
(oxygen saturation, heart rate, respiratory rate, blood pressure) over 2 hours; quality of life at baseline
and at 1 month; number of unscheduled health-care contacts over the subsequent month; and satisfaction
with care.
We planned to recruit 1200 participants divided equally between the three trial arms (400 participants per
arm) to provide the following statistical power: (1) assuming that 80% of patients with acute severe
asthma were admitted to hospital, the study would have 90% power to detect a 10% absolute reduction
in the proportion admitted (i.e. to 70%) for any pair of treatment groups compared (two-sided α = 0.05);
and (2) assuming that 80% of participants have their VAS measured, then the study would have 90%
power to detect a 0.8-cm difference in a 10-cm VAS at 2 hours after treatment initiation (two-sided
α = 0.05). Based on the pre-existing evidence, we selected two primary comparisons for analysis: (1) active
treatment (i.v. and nebulised combined) compared with placebo and (2) i.v. compared with nebulised
treatment. Secondary comparisons were undertaken between i.v. treatment and placebo, and between
nebulised treatment and placebo.
Economic evaluation took an approach consistent with the National Institute for Health and Care
Excellence (NICE) reference case analysis and the perspective of the NHS and personal social services.
Health benefits were measured in two ways using trial data: (1) quality-adjusted life-years (QALYs) using
the European Quality of Life-5 Dimensions (EQ-5D) over a 30-day time horizon and (2) breathlessness on
100-mm VAS at 1 and 2 hours after the initiation of study treatment. Resource use data relating to
hospital care, community health and social services, and medications were collected using either the
hospital records or a patient questionnaire. Productivity loss as a consequence of the number of days
patients took off work during the study was determined using the patient questionnaire and separate
analyses were conducted excluding and including productivity loss. The primary economic analysis was a
cost-effectiveness analysis using the QALYs associated with treatment, focusing on the probability that the
intervention arms would be cost-effective at funding thresholds of £20,000 and £30,000 per QALY.
Additionally, the change from baseline in breathlessness 2 hours after the initiation of study treatment was
used as a secondary cost-effectiveness analysis.
We also planned to undertake an additional analysis of trial data to identify factors that predict
unsuccessful treatment for acute severe asthma. We examined the ability of PEFR, physiological
variables, age, sex, ethnicity, smoking status, and previous hospital high-dependency and intensive care
admissions to predict unsuccessful treatment, defined at two levels: (1) need for critical care (HDU or ICU
admission, ventilator support, respiratory arrest, cardiac arrhythmia or death) and (2) need for emergency
medical treatment, either by return to the ED or unscheduled medical review as an inpatient. Univariate
analysis was undertaken to identify factors that are associated with either outcome (p < 0.15), which were
then entered into multivariate models for each outcome to identify independent predictors of
unsuccessful treatment.Results
Patients were recruited across 34 hospitals between 30 July 2008 and 30 June 2012. Of the 1109 patients
recruited, 25 either withdrew or were recruited in error (protocol violations) and, therefore, 1084 wereNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22included in the analysis. The mean age of patients was 36.1 years; 763 (70%) were female, 974 (90%)
were white and 363 (33%) were current smokers. Salbutamol was given to 1074 out of 1084 participants
(99%) in the ambulance or ED prior to randomisation or up to 4 hours after, with a mean total dose of
8.3 mg [standard deviation (SD) 3.4 mg]. Overall, 1032 out of 1084 (95%) of the trial population received
corticosteroid therapy at some point from 24 hours prior to hospital attendance to 4 hours after
randomisation. Adherence to the trial protocol was high, with 89% receiving the full 100-ml i.v. infusion
and 99% receiving three trial nebulisers.
The proportion of participants admitted to hospital was 285 out of 394 (72%) in the i.v. magnesium
sulphate group, 261 out of 332 (79%) in the nebulised group and 281 out of 358 (78%) in the placebo
group. The odds ratios (ORs) for admission to hospital were 0.84 (95% CI 0.61 to 1.15; p = 0.276) for
active treatment compared with placebo, 0.76 (95% CI 0.53 to 1.10; p = 0.146) for i.v. compared with
nebuliser, 0.73 (95% CI 0.51 to 1.04; p = 0.083) for i.v. compared with placebo and 0.96 (95% CI 0.65
to 1.40; p = 0.819) for nebuliser compared with placebo.
The change in VAS at 2 hours was recorded in 976 out of 1084 (90%) of the cohort. The mean (SD)
change from baseline to 2 hours was 34.3 mm (SD 27.7 mm) in the i.v. group, 28.2 mm (SD 27.4 mm)
in the nebulised group and 31.3 mm (SD 29.4 mm) in the placebo group. The mean differences in
improvement in VAS were 0.0 mm (95% CI –3.7 to 3.7 mm; p = 0.999) for active treatment compared
with placebo, 5.1 mm (95% CI 0.8 to 9.4 mm; p = 0.019) for i.v. compared with nebuliser, 2.6 mm
(95% CI –1.6 to 6.8 mm; p = 0.231) for i.v. compared with placebo and –2.6 mm (95% CI –7.0 to 1.8,
p = 0.253) for nebuliser compared with placebo.
Mean (SD) length of hospital stay was 57.0 hours (SD 75.1 hours) in the i.v. group, 63.2 hours
(SD 79.7 hours) in the nebuliser group and 63.3 hours (SD 84.3 hours) in the placebo group (overall
log-rank test, p = 0.48). The number of participants (%) in each group admitted to ICU was 11 (3%) in the
i.v. group, nine (3%) in the nebulised group and five (1%) in the placebo group (p = 0.161 active vs.
placebo; p = 0.947 i.v. vs. nebuliser). The number of participants (%) admitted to HDU was 23 (6%) in the
i.v. group, 22 (7%) in the nebuliser group and 20 (6%) in the placebo group (p = 0.690 active vs. placebo,
p = 0.661 i.v. vs. nebuliser). The number of participants (%) requiring ventilator support was six (2%) in the
i.v. group, three (1%) in the nebuliser group and four (1%) in the placebo group (p = 0.936 active vs.
placebo; p = 0.458 i.v. vs. nebuliser).
The mean (SD) change from baseline to 2 hours in PEFR was 61.0 l/minute (SD 73.6 l/minute) in the i.v.
group, 58.3 l/minute (SD 77.3 l/minute) in the nebulised group and 62.5 l/minute (69.4 l/minute) in the
placebo group. The mean differences in improvement in PEFR were –2.5 (95% CI –12.5 to 7.5; p = 0.625)
for active treatment compared with placebo, 0.3 (95% CI –11.2 to 11.7; p = 0.964) for i.v. compared with
nebuliser, –2.4 (95% CI –13.6 to 8.8; p = 0.680) for i.v. compared with placebo and –2.6 (95% CI –14.5
to 9.2; p = 0.664) for nebuliser compared with placebo. There were no significant differences in the
primary comparisons for other physiological secondary outcomes (heart rate, respiratory rate, blood
pressure and oxygen saturation).
Rates of adverse events were low, with most of the events recorded being hospital admission due to
underlying asthma or other unrelated conditions. There were two deaths, one cardiac arrest, two cases of
arrhythmia, seven intubations and seven cases requiring non-invasive ventilation (17 patients). The number
(%) of patients reporting any side effect was 61 (15.5%) in the i.v. group, 52 (15.7%) in the nebuliser
group and 36 (10.1%) in the placebo group. The ORs for suffering any side effect were 1.68 (95% CI
1.11 to 2.52; p = 0.014) for active treatment compared with placebo, 1.00 (95% CI 0.66 to 1.52;
p = 0.988) for i.v. compared with nebuliser, 1.68 (95% CI 1.07 to 2.63; p = 0.025) for i.v. compared with
placebo and 1.67 (95% CI 1.05 to 2.66; p = 0.031) for nebuliser compared with placebo.
Satisfaction with care was generally high across all three treatment groups and across most dimensions of
care. The dimensions of care relating to personal interest in the patient and their medical problems, thexvii
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SCIENTIFIC SUMMARY
xviiiamount of time given by hospital staff, and especially advice given about ways to avoid illness and stay
healthy were generally rated lower. There were no significant differences in any of the primary
comparisons between the treatment groups.
The mean EQ-5D scores at baseline were 0.726 (SD 0.354) in the i.v. group, 0.734 (SD 0.327) in the
nebulised group and 0.746 (SD 0.323) in the placebo group. Corresponding scores at 1 month were 0.731
(SD 0.329), 0.721 (SD 0.326) and 0.810 (SD 0.250). There were no significant differences in any of the
comparisons between treatment groups.
The primary economic analysis (without productivity costs) showed mean QALYs per patient of 0.060
(SD 0.0033), 0.060 (SD 0.0028) and 0.063 (SD 0.0030), and mean costs per patient of £1870 (SD £110.80),
£1974 (SD £115.30) and £1610 (SD £89.70) for the i.v., nebulised and placebo groups respectively. Mean
costs per patient increased to £2219 (SD £120.40), £2401 (SD £120.80) and £2007 (SD £107.20),
respectively, when productivity costs were included. There was a 93% and 92% chance that the placebo
had the highest net benefit at thresholds of £20,000 and £30,000 respectively.
The baseline PEFR (p = 0.017), baseline heart rate (p < 0.001), change in PEFR after treatment (p = 0.015),
change in heart rate after treatment (p < 0.001) and the presence of another serious illness (p = 0.019)
predicted the need for critical care. The baseline PEFR (p = 0.010), baseline heart rate (p < 0.001), baseline
respiratory rate (p = 0.017), change in PEFR after treatment (p = 0.003), change in heart rate after
treatment (p = 0.001) and the presence of another serious illness (p = 0.023) predicted the need for
emergency medical treatment within 7 days.Conclusions
We were unable to demonstrate a clinically worthwhile benefit from magnesium sulphate in acute severe
asthma. Intravenous magnesium sulphate was associated with a lower rate of hospital admission than
placebo, but the difference was not significant and there was no evidence of an effect on VAS
breathlessness compared with placebo. There was also no evidence of any clinically worthwhile effect from
i.v. magnesium sulphate on secondary outcome measures, including PEFR. We found no evidence that
nebulised magnesium sulphate was more effective than placebo. In fact, any non-significant trends in the
outcomes involving nebulised magnesium sulphate tended to favour the placebo.
Adherence to the trial protocol was high and most patients received appropriate cotreatments. Patients
generally responded well to treatment with improvements in breathlessness and PEFR and a low rate
of requirement for ventilator support, HDU or ICU care. This suggests that optimal treatment with
salbutamol, ipratropium bromide and corticosteroids may leave little scope for further improvement with
magnesium sulphate.Trial registration
This trial is registered as ISRCTN04417063.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Asthma is a chronic inflammatory disease of the airways characterised by reversible airflow obstructionand bronchospasm. An acute asthma exacerbation (commonly referred to as an asthma attack) is
characterised by shortness of breath, wheezing and chest tightness. Acute asthma was responsible for
55,259 emergency admissions and 153,877 bed-days in England in 2011–12,1 and many more emergency
department (ED) attendances.Management of acute asthmaThe management of acute asthma in the UK NHS is subject to guidance issued by the British Thoracic
Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN).2 The severity of an acute asthma
attack is categorised on the basis of presenting clinical characteristics into near-fatal, life-threatening,
severe, moderate and brittle asthma. Patients with any features of life-threatening or severe asthma are
referred to hospital for emergency treatment.
Prehospital and ED treatment of acute asthma in adults includes supplemental oxygen therapy, oral or
parenteral steroids (prednisolone or hydrocortisone), nebulised β2-agonist bronchodilators (salbutamol or
terbutaline) and nebulised ipratropium bromide. Patients are admitted to hospital if they have any feature
of a life-threatening or near-fatal attack or any feature of a severe attack persisting after initial treatment.
Patients whose peak flow is greater than 75% best or predicted 1 hour after initial treatment may be
discharged from the ED unless they meet any of the following criteria, when admission may be
appropriate: persistent significant symptoms; concerns about compliance; living alone/socially isolated;
psychological problems; physical disability or learning difficulties; previous near-fatal or brittle asthma;
exacerbation despite adequate dose steroid tablets prepresentation; presentation at night; or pregnancy.Magnesium sulphate in acute asthmaMagnesium is an essential mineral nutrient that is present in every cell of every organism. Magnesium-
dependent enzymes appear in virtually every metabolic pathway but notably, magnesium ions block
calcium channels and, thus, affect nerve and muscle activity. Magnesium sulphate has an established
therapeutic role in pre-eclampsia,3 torsade de pointes4 and hypomagnesaemia.5 Its use has also been
explored in ventricular arrhythmias other than torsade de pointes,6 cardiac arrest,7 myocardial infarction,8
atrial fibrillation9,10 and acute asthma.11
The use of magnesium sulphate in acute asthma is based on possible smooth muscle relaxation and
anti-inflammatory action. It can be given via the intravenous (i.v.) or nebulised route and may have a role
augmenting treatment in a therapeutic ‘gap’ between the immediate action of nebulised bronchodilators
and the delayed action of steroids. Doses of 1.2–2 g have been evaluated in acute severe asthma,11
although doses of 4–6 g can be used in other conditions.3 The dose of nebulised magnesium sulphate is
limited by the need to avoid administering a hypertonic nebulised solution and concurrent therapeutic
need for nebulised β2-agonist. The maximum dose is therefore 500mg per nebuliser.1
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INTRODUCTION
2Evidence for intravenous magnesium sulphate in acute asthmaIntravenous magnesium sulphate has been compared with placebo in five meta-analyses,11–15 two of
which analysed adults separately from children.11,14 The meta-analyses included a total of 15 randomised
trials,16–30 nine of which were undertaken in adults.16–24 The trials of adults used a bolus dose of either
1.2 g or 2.0 g of magnesium sulphate, given over 20–30 minutes. Only one trial followed the bolus dose
with an infusion.18
The most recent meta-analysis11 included all nine adult trials.16–24 A variety of methods were used to
measure pulmonary function, therefore these outcomes were pooled by calculating a standardised mean
difference (SMD). The pooled relative risk (RR) for hospital admission after treatment with i.v. magnesium
sulphate was 0.91 [95% confidence Interval (CI) 0.78 to 1.07; p = 0.27] and the pooled SMD in pulmonary
function was 0.15 (95% CI 0.01 to 0.29; p = 0.035). The authors concluded that treatment with i.v.
magnesium sulphate was associated with a modest improvement in pulmonary function, but the clinical
significance of this effect was uncertain. Although there was no significant effect on hospital admission,
the summary estimate included a potentially important reduction in admissions of up to 22%. Existing
evidence was therefore insufficient to either recommend i.v. magnesium sulphate as standard treatment
for acute severe asthma or rule out a potentially valuable role.
One further trial (n = 63) of i.v. magnesium sulphate has been published since the most recent
meta-analysis was undertaken.31 The trial reported a significant effect on predicted forced expiratory
volume in 1 second (FEV1) at 120 minutes (62.84% vs. 56.7%; mean difference = 6.07; 95% CI 1.87 to
10.62; p < 0.01) and fewer patients admitted to hospital in the intervention group (2/30 vs. 9/30). Addition
of these data to the most recent meta-analysis resulted in a pooled SMD of 0.35 (95% CI 0.06 to 0.64;
p = 0.02) and a pooled RR for hospital admission of 0.85 (95% CI 0.68 to 1.06; p = 0.14).Evidence for nebulised magnesium sulphate in acute asthmaNebulised magnesium sulphate has been compared with placebo in three meta-analyses11,32,33 and
eight randomised trials,34–41 of which five were undertaken in adults,34–38 two in children39–40 and one in
a mixed population.41 The most recent meta-analysis11 was the only one to report trials of adults and
children separately. The trial with a mixed population was analysed with the trials of adults. The dose of
magnesium sulphate used ranged from 95 to 500mg, given up to four times, with doses every 20 to
30 minutes. The pooled RR for hospital admission after treatment with nebulised magnesium sulphate
was 0.66 (95% CI 0.44 to 1.00; p = 0.048) and the pooled SMD in pulmonary function was 0.20
(95% CI –0.02 to 0.42; p = 0.076). Although the effect of nebulised magnesium sulphate on hospital
admissions just reached significance, most of the admissions in this analysis were in one trial,36 and the
effect was not consistent across the other trials. The authors concluded that the existing evidence was
inadequate to either support nebulised magnesium sulphate as standard treatment for acute severe
asthma or rule out a potentially valuable role.Comparison between intravenous and nebulised
magnesium sulphateNo previous trials have compared i.v. with nebulised magnesium sulphate.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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nebulised magnesium sulphateThe existing evidence for both i.v. and nebulised magnesium sulphate suggests a potentially worthwhile
effect on pulmonary function and hospital admissions, but estimates of effect are imprecise and include
the possibility of either no clinically worthwhile effect or a substantial effect. Furthermore, the existing
evidence is subject to the following limitations:
1. Most previous trials were relatively small and powered to detect changes in pulmonary function rather
than hospital admission.
2. Even if meta-analysis suggests a statistically significant difference in pulmonary function it is not clear
whether such changes are important to patients or affect their clinical outcome.
3. Factors such as publication bias may influence selection of studies into meta-analysis, leading to
overestimates of effectiveness. It has been noted that 35% of subsequent large trials conflict with the
results of a previous meta-analysis.42
4. The clinically important change in admission rate in patients with severe asthma identified in the
meta-analysis by Rowe et al.12 was based on post-hoc subgroup analysis.
5. No previous trials have included a head-to-head comparison of nebulised with i.v. magnesium sulphate.Current use of intravenous and nebulised magnesium sulphate
in the National Health ServiceCurrent BTS/SIGN guidelines for the management of acute asthma2 state that there is limited evidence
that, in adults, magnesium sulphate has bronchodilator effects and, although experience suggests that
magnesium sulphate is safe when given by the i.v. or nebulised route, trials comparing these routes of
administration are awaited. The guidelines suggest considering giving a single dose of i.v. magnesium
sulphate to patients with acute severe asthma who have not had a good initial response to inhaled
bronchodilator therapy or who have life-threatening or near-fatal asthma. Similar advice is provided by
guidelines used in the USA.43
A postal survey of the use of magnesium sulphate in the treatment of acute asthma in the ED was
undertaken in the UK in 2009.44 The lead clinician of each ED was mailed a survey asking about the use of
magnesium sulphate in his or her department and 180 out of 251 responded (72%). Magnesium sulphate
was reportedly used in 93% of the EDs, mostly because it was expected to relieve breathlessness (70%) or
reduce critical care admissions (51%). Most departments used magnesium sulphate for patients with acute
severe asthma (84%) and life-threatening exacerbations (87%), with 68% stating they would give the
drug if there was no response to repeated nebulisers. In comparison, nebulised magnesium sulphate was
used in only two EDs (1%). The main reason given for not administering via a nebuliser was insufficient
evidence (51%). The authors commented that the reported use of i.v. magnesium sulphate was more
extensive than current guidelines or available evidence appeared to support.Research objectivesWe aimed to measure the clinical effectiveness and cost-effectiveness of i.v. and nebulised magnesium
sulphate in acute severe asthma and, thus, determine whether or not either should be standard first-line
treatment for patients presenting to the ED with acute severe asthma.3
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INTRODUCTION
4We planned to test the following specific hypotheses:
1. intravenous or nebulised magnesium sulphate will reduce the proportion of patients who require
admission at initial presentation or during the following week
2. intravenous or nebulised magnesium sulphate will improve patient assessment of their breathlessness
over 2 hours after initiation of treatment.
We also planned to measure the effect of i.v. or nebulised magnesium sulphate on:
1. length of hospital stay and use of high-dependency unit (HDU) or intensive care unit (ICU)
2. mortality, adverse events and use of respiratory support
3. change in peak expiratory flow rate (PEFR) and physiological variables after initial treatment
4. patient-reported health utility
5. patient satisfaction with care
6. use of health and social services over the following month
7. time taken by patients off work
8. health and social care costs and productivity losses.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The 3Mg trial was a multicentre, double-blind, placebo-controlled, three-arm, randomised trial andeconomic analysis of i.v. or nebulised magnesium sulphate in acute severe asthma. The trial took place
in 34 EDs in England and Scotland.Recruitment and allocation of participantsAdults (age over 16 years) attending the ED with acute severe asthma were recruited to the trial. Acute
severe asthma was defined as acute asthma with one or more of the following: PEFR < 50% of best or
predicted; respiratory rate > 25 breaths per minute; heart rate > 110 beats per minute; or inability to
complete sentences in one breath. The percentage of best or predicted PEFR was calculated using the
patient’s recent best PEFR (within 2 years) if it was known. If the recent best PEFR was not known,
the predicted PEFR from age and height charts was used. This approach is recommended in BTS/SIGN
guidance2 and was used to calculate all estimates of the percentage of best or predicted PEFR used in the
trial. For convenience we use the term ‘% predicted PEFR’ to encompass all such estimates.
The following individuals were excluded:
1. patients with life-threatening features, defined as one or more of the following: oxygen saturation
< 92% despite supplemental oxygen; silent chest; cyanosis; poor respiratory effort; bradycardia;
arrhythmia; hypotension; exhaustion; coma; or confusion
2. patients with a contraindication to either nebulised or i.v. magnesium sulphate: pregnancy; hepatic or
renal failure; heart block; or known hypermagnesaemia
3. patients who were unable to provide written or verbal consent
4. previous participants in the 3Mg trial
5. patients who had received i.v. or nebulised magnesium sulphate in the 24 hours prior to attendance at
the ED.
The final exclusion criterion was added as a protocol amendment during the trial.
Anonymised basic details (age, sex, time and date of ED attendance) were collected from all potentially
eligible patients to allow completion of a CONsolidated Standards Of Reporting Trials (CONSORT) flow
chart. Patients were identified by ED medical staff, who completed a patient recruitment form
(see Appendix 1) to verify that the patient met the eligibility criteria and to record that consent was taken
prior to randomisation. Eligible patients were initially given a brief information sheet with details of the
study design, trial treatments and potential side effects (see Appendix 2). When their condition permitted,
they were given a full information sheet with further details on trial processes and requirements (see
Appendix 3). All patients were required to give consent before being recruited to the trial. If the patient’s
condition permitted, full written consent was taken before recruitment using the Research Ethics
Committee (REC)-approved consent form (see Appendix 4). If not, verbal consent was obtained from the
patient, recorded on the consent form and written consent requested as soon as the patient’s condition
improved. No provisions were made for personal or professional legal representation or for recruitment
before consent. Therefore, any patient unable to provide written or verbal consent was excluded from the
trial. Both oral and written consent were taken in the presence of a witness who also signed the consent
form, in addition to the person taking consent.
Once eligibility had been confirmed and consent acquired, the participants were randomly allocated to a
treatment group. The recruiting clinician accessed a web-based randomisation system or automated
telephone hotline provided by the Sheffield Clinical Trials Research Unit (CTRU) in partnership with
epiGenesys (a University of Sheffield subsidiary software development company) and participants were5
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METHODS
6allocated to a numbered treatment pack kept in the ED. The randomisation system only revealed the
allocated pack number after patient details had been recorded and the patient irreversibly entered into the
trial. A simple randomisation sequence was used in the first 20 hospitals open to recruitment, as planned
in the protocol.45 However, recruitment rates were lower than anticipated and, therefore, additional
hospitals were opened to recruitment. To reduce the risk of random imbalances in the number allocated to
each arm of the trial, blocked randomisation (block sizes of four or six), stratified by hospital, was used for
subsequent centres. To avoid the risk of subversion of the randomisation process in these hospitals,
decisions regarding the randomisation sequence were made independently by the CTRU and were not
communicated to the investigators.
Each treatment pack contained an i.v. infusion and nebuliser solutions, either of which could be active
treatment or placebo. Participants, hospital staff and research staff were all blind to allocated treatment,
unless the formal unblinding procedure was undertaken. An emergency unblinding (code-break) procedure
was in place to enable hospital staff to reveal the allocation of treatment when it was essential to know
for their on-going clinical care whether or not the patient had received magnesium sulphate. A 24-hour
unblinding service was available via the randomisation system (online or telephone), which immediately
provided treatment allocation to the site and automatically alerted the study team and local principal
investigator (PI) by e-mail that a participant had been unblinded. In case the online and telephone systems
were unavailable, emergency unblinding envelopes were also prepared by the pharmacy production unit
according to the randomisation schedule and stored with the investigational medicinal products (IMPs) at
site. Tamper stickers were checked regularly to ensure that envelopes had not been opened and were
returned, still sealed, to the central study team to ensure full accountability. If an envelope was opened it
was reported to the study team and recorded as a participant unblinding.InterventionsPatients were randomised to one of three treatment arms. Each patient received one i.v. and one
nebulised treatment (consisting of three nebuliser vials given consecutively). The i.v. infusions and
nebuliser vials were prepared as apparently identical solutions, with identical primary packaging and
labelling to ensure blinding. Blinded treatment packs were assembled and labelled with a participant
number in accordance with a randomisation schedule supplied by the CTRU. The three treatment arms
are shown in Table 1.
All three groups received standard therapy at the discretion of the treating physician, but guided by
BTS/SIGN guidelines2 and the 3Mg Clinical Protocol (see Appendix 5). Recommended standard therapy
included supplemental oxygen, nebulised salbutamol, nebulised ipratropium bromide and oral
prednisolone, administered during recruitment, followed by up to 5 mg of salbutamol added to each trial
nebuliser. The BTS/SIGN guidelines2 do not recommend magnesium sulphate, but suggest that i.v. use
should be considered in patients with life-threatening features or those with severe asthma who do notABLE 1 Treatment arms
Treatment arm Intravenous infusion Nebulisers
1 i.v. magnesium sulphate, 8mmol (2 g) in 100ml
of water for injections, adjusted to isotonicity
with sodium chloride, given over 20 minutes
7.5-ml vial of 0.9% saline, given three times
20 minutes apart
2 i.v. 0.9% saline, 100ml given over
20 minutes
7.5-ml vial of 2 mmol (500mg) magnesium
sulphate, given three times 20 minutes apart
3 i.v. 0.9% saline, 100ml given over 20 minutes 7.5-ml vial of 0.9% saline, given three times
20 minutes apartTNIHR Journals Library www.journalslibrary.nihr.ac.uk
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recommend its use in patients unresponsive to treatment. During the trial we identified the occasional use
of magnesium sulphate at an early stage of treatment of patients without life-threatening features. We
therefore added an additional exclusion criteria that patients must not have received magnesium sulphate
in the previous 24 hours before entry into the study.
Patients were managed in the ED and data collected until 2 hours after randomisation. At this point, if not
already undertaken, a final disposition decision (hospital admission or discharge) was made.Outcome measuresTwo primary outcomes were specified in the trial protocol:
1. The health service primary outcome – the proportion of patients admitted to hospital, either after ED
treatment or at any time over the subsequent week.
2. The patient-centred primary outcome – the patient’s visual analogue scale (VAS) for breathlessness over
2 hours after initiation of treatment.
Secondary outcomes included mortality; adverse events; the use of ventilation or respiratory support;
length of hospital stay; use of HDU or ICU; change in PEFR and physiological variables (oxygen saturation,
heart rate, respiratory rate, blood pressure) over 2 hours; quality of life at baseline and at 1 month
[measured by European Quality of Life 5-Dimensions (EQ-5D)]; number of unscheduled health-care
contacts (ED, walk-in centre or general practitioner attendances) over the subsequent month; and
satisfaction with care.
The two primary outcome measures were selected to identify important changes in patient management
and symptoms of asthma. The primary outcome of hospital admission included any admission over the
following week, because this time period would encompass the expected duration of an asthma
exacerbation and a typical course of associated treatment. Admission during this time therefore
represented an overall failure of treatment, whereas admission later than 1 week was considered a
separate episode.
The VAS and the Borg scale have both been used to measure breathlessness during exercise,46 but have
only recently been tested in acute asthma. Kendrick et al.47 showed that the Borg scale correlated with
measures of respiratory function in a cohort of patients with asthma or chronic obstructive pulmonary
disease, whereas Karras et al.48 and Gupta et al.49 showed correlation between the VAS and measures of
respiratory function in cohorts with acute asthma. The study by Karras48 also showed that the mean VAS
change among patients who reported their asthma to be ‘a little better’ after treatment was 22 mm on a
100-mm VAS and concluded that this represented a minimum clinically significant change. On the basis of
these studies we concluded that the VAS was the best validated measure, offering a simple and reliable
means of measuring symptomatic breathlessness in people with acute asthma, with an estimate of the
minimum clinically significant change in VAS.
Outcomes were measured in two phases: (1) over 2 hours after randomisation and (2) at 1 month after
attendance. During the first phase we measured variables that reflect patient response to emergency
treatment, such as VAS, PEFR and physiological variables. During the second phase we measured variables
that reflect the overall patient experience of an asthma attack and its subsequent treatment, such as
adverse events, use of health services, satisfaction with care and quality of life.7
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METHODS
8Data collection and managementA recruitment form was completed for all patients attending the ED with acute severe asthma at
participating sites. These data were used to complete the CONSORT flow chart and generate reports on
non-recruited patients for discussion at management group meetings.
Clinical staff recorded baseline data, details of co-interventions and outcome data up to 2 hours after
randomisation on the paper case report form (CRF) (see Appendix 6). Further data were collected up to
1 month after recruitment by research nurses using routine data sources and by patient self-completion
questionnaire. A postal survey consisting of the EQ-5D, a health-care resource use questionnaire, and a
patient satisfaction questionnaire was mailed to all participants who were alive and had not withdrawn
from the trial 1 month after recruitment (see Appendices 7 and 8). A repeat mailing was undertaken for all
non-responders at 2 weeks, with telephone completion of the EQ-5D attempted 2 weeks later for
non-responders to either mailings. Patients who had not responded to mail or telephone contact by
8 weeks after study entry were recorded as lost to follow-up for questionnaire data.
Trial data were entered via web-based interface to a database developed in-house by the CTRU.
The system, and its underlying database, resided on a server in Corporate Information and Computing
Services at the University of Sheffield. Automated backups were made nightly. Prospect was accessed
remotely via a secure web browser and all data transmissions were encrypted. Access was restricted by
username and password (issued by the CTRU) and an automated audit trail recorded when (and by which
user) records were created, updated or deleted. The profile of each user was set to allow only the
appropriate information to be viewed and edited, e.g. site data inputters could only enter and view data
about patients from their own sites. Quality control procedures were applied to validate the trial data.
Error reports were generated where data clarification was required and data queries resolved by research
nurses at sites. All activities were performed in accordance with Sheffield CTRU standard operating
procedures (SOPs).Proposed sample sizeWe planned to recruit 1200 participants, divided equally between the three trial arms (400 participants per
arm). We anticipated that the hospital admission would be recorded for all participants, but that a
proportion of cases would not have VAS measured. The sample size would therefore provide the following
statistical power:
1. Proportion of patients admitted – assuming that 80% of patients with severe asthma are admitted after
ED management, the study would have 90% power to detect a 10% absolute reduction in the
proportion admitted (i.e. to 70%) for any pair of treatment groups compared (α = 0.05).
2. VAS breathlessness – assuming that the standard deviation on a 100-mm VAS is 3 cm, that 2.2 cm
represents a minimum clinically significant difference48 and that 20% of participants will not have their
VAS measured, the study would have 90% power to detect a 8-mm difference in a 100-mm VAS at
2 hours after treatment initiation (α = 0.05).Statistical analysis
Analysis of coprimary outcomes
For the health service primary outcome, patients were considered to have been admitted if either (i) they
had not been discharged within 4 hours and/or (ii) if they were recorded as having been readmitted at any
point within 7 days following randomisation. The proportion admitted was analysed using logistic
regression. We anticipated that data would be missing from only a very small proportion of the trialNIHR Journals Library www.journalslibrary.nihr.ac.uk
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case analysis.
For the patient-centred primary outcome, breathlessness was defined as the change in VAS from baseline
to 2 hours and was analysed using linear regression. As both missing data and measurements outside
the allotted time window were anticipated, the analysis plan proposed three analyses:
1. ‘As is’ – complete case analysis, no adjustment is made for timing.
2. ‘Imputed’– measurements more than ± 15 minutes from their scheduled time were adjusted by linear
interpolation or extrapolation.
3. Multiple imputation by chained estimation. Missing 2-hour VAS scores (n = 108; 10%) were imputed
based on age, sex, smoking status, previous admission for asthma, previous admission to ICU or HDU
for asthma, time since last admission for asthma, baseline and 1-hour VAS, PEFR and heart rate
over 2 hours’ observations, and status at 4 hours (i.e. discharged or admitted/awaiting decision).
Analysis was undertaken on an intention-to-treat basis. Patients were removed from analysis post
randomisation only if recruitment was an unequivocal protocol violation (i.e. no consent had been
recorded or if they had previously been recruited) or if the patient withdrew from the trial prior to any
treatments having been administered. In all other cases, participants were analysed in accordance with
the groups they were allocated to regardless of whether or not they actually completed their allocated
treatment. A secondary, per-protocol analysis excluded participants who did not receive treatment,
defined as a minimum nebulised dosage of 7.5 ml (the equivalent of one nebuliser) or 50 ml of i.v. volume
(50% of the i.v. dose).
The primary and most of the secondary analyses included two covariates: treatment group and centre
(hospital). For the purposes of the analysis, hospitals recruiting fewer than 10 patients in total were
combined into one group for analyses in which centre was used as a covariate. The robustness of the
findings to potential differences in baseline characteristics was assessed, in particular the initial
breathlessness (VAS) and age.
We used Simes’ method,50 which is a modification of the Bonferroni method but has better power to
adjust for multiplicity arising from having two primary outcomes. However, we did not adjust the CIs
associated with the estimate of the treatment effect with each outcome. We tested the two hypotheses
simultaneously through the analysis of variance. With three groups (A = nebuliser, B = i.v. and C = control)
we had two degrees of freedom for analysis, which we split into two orthogonal contrasts (–2, +1, +1) to
contrast both active treatments compared with control and (0, –1, +1) to contrast the active treatments.Secondary outcomes
The length of hospital stay was analysed using a log-normal distribution, which allowed for interval
censoring of non-admitted patients and right censoring of hospital duration among those still in hospital
30 days after randomisation. PEFR and physiological measures were analysed in the same manner as
breathlessness. All secondary analyses were undertaken as complete case, intention-to-treat analyses.Subgroup analyses
We prospectively defined three subgroup analyses, within which patients were stratified on the basis of:
1. Asthma severity, according to whether baseline PEFR (pretreatment PEFR as a percentage of predicted
value) was above or below median baseline PEFR. A previous meta-analysis12 suggested that i.v.
magnesium sulphate is more effective in patients with severe asthma.
2. Age, above or below 50 years. Older patients with a diagnosis of asthma are more likely to have
chronic respiratory disease that may be less responsive to treatment with magnesium sulphate.
3. Treatment before arrival. We recruited patients on arrival at hospital, thus testing magnesium sulphate
as a first-line treatment. However, some patients received prehospital treatment with nebulisers, thus9
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METHODS
10making magnesium sulphate, in effect, a second-line treatment. Patients with severe asthma after
receiving prehospital treatment are likely to have more severe asthma than those presenting without
prehospital treatment.Economic evaluationThe economic evaluation took an approach consistent with the National Institute for Health and Care
Excellence (NICE) reference case analysis.51 The perspective taken was that of the NHS and personal social
services. Health benefits were measured in quality-adjusted life-years (QALYs) using the EQ-5D and the
time horizon over which health benefits were derived was 30 days. Health benefit was also measured by
assessing breathlessness on a 100-mm VAS at 1 and 2 hours after the initiation of study treatment. The
data collected 2 hours after the initiation of treatment were used in the cost-effectiveness analysis.
The following resources were identified as being important and collected using either the CRF or
patient-completed questionnaire:
l trial medication
l ICU – asthma related (days)
l HDU – asthma related (days)
l ward – asthma related (days)
l ICU – non-asthma related (days)
l HDU – non-asthma related (days)
l ward – non-asthma related (days)
l telephone health advice [e.g. general practitioner (GP), NHS Direct] (number of times used)
l GP surgery consultations (number of times used)
l GP home visits (number of times used)
l nurse home visits (number of times used)
l social worker visits (number of times used)
l ED attendances (number of times used)
l attendance at hospital as an outpatient (number of times used)
l asthma-related concomitant medications: salbutamol, prednisolone, ipratropium bromide, salmeterol
xinafoate/fluticasone propionate (Seretide®, GlaxoSmithKline), budesonide (Pulmicort®, AstraZeneca),
montelukast, beclometasone dipropionate (Clenil® Modulite®, Chiesi Ltd), aminophylline,
theophylline, hydrocortisone, tiotropium (Spiriva®, Boehringer Ingelheim Ltd), magnesium sulphate,
salmeterol, ipratropium bromide/salbutamol (Combivent®, Boehringer Ingelheim) and terbutaline
(Bricanyl®, AstraZeneca UK Ltd).
Inpatient stays and medications were collected via CRFs, with the remainder collected by patient
questionnaire. Productivity loss as a consequence of the number of days patients took off work during the
study was collected using the patient questionnaire and separate analyses were conducted excluding and
including productivity loss.
Unit costs for medication were taken from the British National Formulary (BNF),5 with the implied dose
being that of the most common recorded within the trial (Table 2). Other unit costs were derived primarily
from NHS reference costs52 and the Personal Social Service Research Unit annual unit costs publication.53
NHS reference costs were inflated to 2011/12 prices using the gross domestic product deflator (as the
relevant Hospital and Community Health Services Index figure is not yet available). The costs of NHS Direct
advice were estimated from an evaluation of this service54 and the costs of production losses were
estimated using data from the Office for National Statistics.55 These unit costs are shown in Table 3.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 2 Unit costs of medications
Item of resource (medicationsa) Route Dose Cost per doseb (£)
Treatment arm 1 (2mg of i.v. magnesium sulphate) – – 7.39
Treatment arm 2 (2mg of nebulised magnesium sulphate) – – 7.39c
Treatment arm 3 (saline) – – 0
Aminophylline Oral 1 × 225mg 0.04
Aminophylline i.v. 2 × 10-ml ampoule 1.56
Beclometasone dipropionate Inhaled 2 × 100 µg 0.07
Combivent Nebulised 1 × 2.5ml 0.40
Hydrocortisone Oral 1 × 20mg 1.53
Hydrocortisone i.v. 2 × 100mg 2.16
Ipratropium bromide Nebulised 1 × 500 µg 0.37
Ipratropium bromide Inhaled 2 × 20 µg 0.05
Magnesium sulphate i.v. 1 × 2 g 7.39
Methylprednisolone Oral 2 × 16mg 1.14
Montelukast Oral 1 × 10mg 0.96
Prednisolone Oral 8 × 5mg 0.35
Pulmicort Nebulised 1 × 1mg 30.30
Pulmicort Inhaled 1 × 200 µg 0.12
Salbutamol i.v. 1 × 5mg 0.19
Salbutamol Nebulised 1 × 5mg 0.19
Salbutamol Inhaled 2 × 100mg 0.02
Salmeterol (Serevent®, GlaxoSmithKline) Inhaled 2 × 25 µg 0.46
Seretide Inhaled 2 × 250 µg 0.60
Terbutaline Inhaled 1 × 500 µg 0.07
Theophylline Oral 1 × 200mg 0.05
Tiotropium Inhaled 1 × 18 µg 1.06
a Dose represents most common for drug/route.
b Any associated devices and consumables not included.
c Nebulised magnesium sulphate not available in BNF. Same price as 2-g prefilled syringe assumed.
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TABLE 3 Non-medication unit costs
Item of resource Cost per unit (£) Year Citation
Telephone advice from NHS Direct 25 2011/12 54
GP surgery consultations 37 2011/12 53
GP home visits 124 2011/12 53
Nurse home visits 37 2011/12 53
Social worker visits 108 2011/12 53
ED attendance 96 2011/12 52
Outpatient visits – asthma related 133 2011/12 52
Inpatient days – asthma related 358 2011/12 52
Inpatient days – asthma and other related 261 2011/12 52
ICU days 868 2011/12 52
HDU days 623 2011/12 52
Days off work 101 2011/12 55
METHODS
12Quality-adjusted life-years were calculated for each patient over the duration of the study using the
EuroQoL tariff56 and by applying the trapezoidal rule based on data at baseline and at 30 days. The
change from baseline in breathlessness 2 hours after the initiation of study treatment, as measured using a
100-mm VAS, was calculated for each patient. Reduction from baseline is defined as minus one times the
change from baseline to reflect the fact that a reduction in breathlessness is a positive outcome.
The primary analysis was a cost-effectiveness analysis using the QALYs associated with treatment.
Additionally, the change from baseline in breathlessness 2 hours after the initiation of study treatment, as
measured using a 100-mm VAS, was used as a secondary cost-effectiveness analysis. The focus of the
analysis is on the probability that the intervention arms are cost-effective at funding thresholds of £20,000
and £30,000 per QALY. In addition, cost-effectiveness acceptability frontiers are presented over the range
£0–100,000 per QALY. As with all cost-effectiveness analyses, it is necessary for the measure of
effectiveness to be linear in the sense that the value of an incremental increase of E units of effectiveness
is EK, where K is the value to the decision-maker of increasing effectiveness by one unit. Unlike QALYs, it
is not clear how much value a decision-maker may give to a unit reduction in breathlessness on the VAS
scale, but is likely to be much less than that for a QALY. Cost-effectiveness acceptability frontiers are
presented over the range £0–1000 per unit reduction in breathlessness. Sensitivity analyses were
performed incorporating production losses (i.e. time taken from paid employment).
Missing data were imputed using a single-value imputation approach. A multiple imputation algorithm
was attempted but it failed to converge, possibly as a consequence of the large number of missing data
associated with some outcome measures and the assumptions being made about their underlying
probability distributions in the multiple imputation algorithm.
The analysis was initially planned to use bootstrapping, but this was replaced by an analysis using a
Bayesian approach using a bivariate normal likelihood function for the effectiveness and total cost.57 The
bivariate normal likelihood function is justified by appealing to the central limit theorem, which says that
for data from any underlying probability distribution with finite mean and variance, the distribution of the
sample means will tend to be a normal distribution with sufficiently large sample sizes. This change was
undertaken in advance of the analysis commencing.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Medical Research Council, UK).58 Weak prior information was included in the analysis. The model
converged very quickly but for accuracy and precision purposes the results are based on 100,000 Markov
chain Monte Carlo iterations after a burn-in of 25,000 iterations.
With sample sizes as large as those in this study, the results are expected to be similar to what would
have been generated using bootstrap or a more exact approach that specifically models the underlying
distribution of the derived effectiveness and total cost data. Nevertheless, a benefit of this approach is that
it allows a more direct interpretation about the probability associated with the parameters of interest
(i.e. population mean incremental cost and effectiveness) and the probability of positive net benefit.Predictors of unsuccessful treatmentTo maximise the value of this project, we planned to undertake an additional analysis of trial data to
identify factors that predicted unsuccessful treatment for acute severe asthma. Predicting unsuccessful
treatment would be helpful for deciding which patients need asthma nurse review after discharge,59 which
need hospital admission and which need HDU or ICU support. Currently these decisions are made largely
on PEFR recordings,2 although it is not clear how useful these are as predictors of relapse.
Data collection for the trial included variables that may be potentially useful predictors of unsuccessful
treatment, such as baseline and post-treatment PEFR, physiological variables, age, sex, smoking status,
and previous hospital, HDU and ICU admissions. We examined the ability of these factors to predict
unsuccessful treatment, defined at two levels: (1) need for critical care, i.e. HDU or ICU care, airway
management, respiratory support or cardiopulmonary resuscitation or respiratory arrest, cardiac arrhythmia
or death within 7 days of initial attendance; and (2) need for emergency medical treatment (including
critical care) within 7 days of presentation, either by attendance at the ED or unscheduled inpatient review.
Models were fitted separately for the two definitions. For each, an initial screening phase assessed
potential covariates, with those achieving a minimum significance level of p < 0.15 retained for the
multivariable modelling. Outcomes were modelled using logistic regression. Continuous covariates
(physiological variables, PEFR and age) were modelled using fractional polynomials,60 but the resultant
model compared with two alternative functional forms (linear and quadratic) to assess whether or not a
simpler model could achieve an adequate fit. Predictive ability was assessed by calculating the area under
the receiver operator characteristic (AUROC) curve of the model. Internal validation was performed by
two methods: (1) bootstrap validation, assessing the robustness of model covariates and (2) cross-validation.
The model was fitted separately to the following subgroups defined by (i) seasonality (October–March
vs. April–September), (ii) time period (2008–10 vs. 2011–12) and (iii) type of hospital (teaching
vs. non-teaching). In each case the resultant models were assessed for consistency between
the subgroups.
For each definition, three models were incrementally compared:
1. a model based solely on %PEFR at admission
2. a model using the best-fitting combination of baseline (pretreatment) physiological covariates
3. a model incorporating change in physiological measures over 2 hours, in addition to those used in
model 2.Ethical issuesThe trial was undertaken in accordance with the Medicine for Human Use (Clinical Trials) Regulations
200461 and subsequent amendments, and was approved by the Scotland A REC. The main ethical issue13
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14was that patients with acute severe asthma may lack capacity to provide informed consent or the ability to
complete a written consent form, yet the very nature of the trial required that recruitment should take
place quickly in an emergency and include acutely ill patients.62,63 We initially planned to use personal or
professional legal representatives to provide proxy consent for patients lacking capacity. However, on the
advice of the ethics committee this provision was dropped and only patients able to provide some form of
consent were recruited to the trial. In addition to the person taking consent, a witness also had to sign the
consent form to verify that the patient had capacity to give informed consent. It was felt that patients who
were too ill to consent were likely to have life-threatening asthma and that excluding patients lacking
capacity would not compromise validity.
Participants were therefore only recruited into the trial if they could provide written or verbal-informed
consent. We used the following process for seeking consent, based on the Medicine for Human Use
(Clinical Trials) Regulations 2004 and subsequent amendments, and taking into account the ethics
committee review:
1. All patients were given emergency treatment with supplemental oxygen, salbutamol nebuliser and
ipratropium bromide nebuliser while consent was being sought. Initial investigations, such as arterial
blood gas sampling and chest radiography, continued simultaneously.
2. Potential participants were given a brief initial information sheet (see Appendix 2) and asked if they
wished to consider participation in the trial.
3. Those patients that would consider participation were given further verbal information.
4. Potential participants who were able to express their consent and were able to complete the consent
form (see Appendix 4) were asked to provide written consent.
5. Potential participants who were able to express their consent but unable to complete the consent form
as a result of their acute illness were recorded on the consent form as having provided verbal consent.
6. If the potential participant was not competent to give written or verbal consent, then he or she was not
recruited into the trial.
7. Every recruited participant was reviewed at regular intervals during their treatment. As soon as their
condition improved, they were provided with the full information sheet (see Appendix 3). Those
participants who had completed a written consent form were asked if they were happy to remain in
the trial. Those participants who had not completed a written consent form were asked to do so.
The risks to participants in this trial were considered to be low. Magnesium sulphate has been used by i.v.
and nebulised routes in a number of trials and, although unlicensed, has frequently been used in the
treatment of acute severe asthma. It is also included as a possible treatment for acute asthma in BTS/SIGN
guidelines.2 Although minor side effects such as nausea or flushing are common, serious side effects
(arrhythmias and coma) are uncommon. Potential participants were advised of these risks when they were
invited to participate.Research governanceThe trial was conducted in accordance with Medical Research Council (MRC) Guidelines for Good Clinical
Practice (GCP)64 and the Medicines for Human Use (Clinical Trials) Regulations 2004. Sheffield Teaching
Hospitals (STH) NHS Foundation Trust was the trial sponsor. The trial was an IMP trial covered by clinical
trial regulations from the Medicines and Healthcare products Regulatory Agency (MHRA). A clinical trial
authorisation was applied for and received from the MHRA. A site agreement between the sponsor,
participating site, CTRU and University of Sheffield outlined responsibilities of all parties and was signed
prior to commencement of recruitment at sites.
All clinicians responsible for recruiting patients to the trial were required to complete training in GCP. This
presented substantial logistical barriers as, at the time the trial commenced, there was no requirement for
GCP training as part of emergency medicine specialist training and there was a rapid turnover of doctors inNIHR Journals Library www.journalslibrary.nihr.ac.uk
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training curriculum, developed a GCP training package and made it available through the College of
Emergency Medicine website, and promoted GCP training in the Emergency Medicine Journal.65
Blinded treatment packs were manufactured in conjunction with the CTRU, initially by STH NHS
Foundation Trust Pharmacy Production Unit at the Royal Hallamshire Hospital (RHH) and subsequently by
Tayside Pharmaceuticals. All products were checked by a qualified person (QP) prior to release. The change
to Tayside Pharmaceuticals was necessary as RHH did not maintain its manufacturer’s authorisation for
IMPs, the manufacturer’s/importer’s licence (MIA), after the production of the first batch of IMPs. However,
RHH continued to label the kits with a randomisation code in accordance with a randomisation schedule
supplied by the CTRU and distribute kits to sites. This assembly service is permitted under the exemption
for hospitals (regulation 37, UK SI 2004/1031). The pharmacy production units maintained an
investigational medical products dossier (IMPD) (see Appendix 9) and relevant documentation.
Blinded treatment kits were manufactured, assembled and labelled as per European Commission Good
Manufacturing Practice annex 13 requirements66 to enable the treatment to be identified and the batch
source of the materials traced. Treatment kits consisted of a box containing an infusion bag and three
nebuliser solution vials. Boxes carried an outer label identifying the trial and kit number. An unblinded kit
number list and randomisation schedule (accessed via the online randomisation system using a pharmacy
production unique username) allowed the RHH production unit to identify which arm of the trial each kit
belonged to, and label the kits with a randomisation code. IMPs were supplied on a demand basis to the
participating sites with minimal waste of materials. Treatment kit accountability logs were maintained by
all parties (production units, CTRU, sites, hospital pharmacies), to allow full reconciliation of IMPs including
assignment to patients.
Three committees were established to govern the conduct of the trial: the Trial Steering Committee (TSC),
the independent Data Monitoring and Ethics Committee (DMEC) and the Project Management Group
(PMG). These committees functioned in accordance with Sheffield CTRU SOPs.
The TSC consisted of four independent members [Professor of Respiratory Medicine (as chairperson),
statistician, consultant in emergency medicine, patient representative] and three members of the trial team
(chief investigator, emergency medicine co-applicant on the grant and the project manager). The TSC
supervised the trial and in particular, the progress of the trial, adherence to protocol, patient safety and
consideration of new information. The TSC made the decisions on how to proceed with the trial following
recommendations from the DMEC.
The DMEC consisted of an independent statistician, a respiratory consultant and an emergency medicine
consultant. The principal duty of the DMEC was patient safety. The DMEC agreed a charter stating the
intended interim analyses and stopping rules for the study, and made recommendations to the TSC and
PMG. The DMEC could make recommendations to:
(a) continue recruiting
(b) stop the trial
(c) continue, with modification to the protocol.
The PMG consisted of the chief investigator, co-applicants, project manager and co-ordinators, statistician,
research nurses and sponsor representative. The role of this group was to oversee the day-to-day
management of the trial.15
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16Reporting of serious adverse eventsSerious adverse events (SAEs) were reported in accordance with the 3Mg trial SAE reporting protocol and
the sponsor’s (STH) SOP67 for reporting, managing and recording adverse events for STH studies. All SAEs
occurring within 30 days of recruitment to the trial were reported immediately to the sponsor on learning
of their occurrence. Site trial staff and delegated ED staff were responsible for recording all adverse events
that were reported by the participant and making them known to the PI. An investigators’ brochure (IB)
was maintained by the trial team as the reference safety information for reporting SAEs (see Appendix 10).
Magnesium sulphate is a naturally occurring compound that is a normal constituent of the human body
and, since the trial involved administering magnesium sulphate over a single 1-hour period, it was
expected that any effect on other medications would be limited to the first few hours after administration.
Thus, the SAE reporting procedure for the 3Mg trial only recorded those concomitant medications given in
the 48-hour period after the trial drug was administered.Reporting of protocol violations and deviationsProtocol violations and deviations were reported in accordance with the 3Mg and STH protocol violation
and deviation SOPs. The site research nurse was responsible for reviewing the participant CRF and ED
notes after entry into the trial to determine if treatment was given in accordance with the protocol,
consent was obtained correctly and by a suitably trained and delegated doctor, and that the patient met
the eligibility criteria. Any suspected protocol violation or deviation was reported to the local PI and to the
central 3Mg team. The chief investigator/CTRU reviewed and confirmed if the incident was a violation/
deviation and reported to the sponsor. Participants continued to participate in the trial except if the patient
had given no informed consent or if they have requested to be withdrawn from the study. Fully consented
patients enrolled on the trial were followed up and analysed as per intention-to-treat analysis outlined in
the 3Mg protocol (see Appendix 11).Trial monitoringThroughout the trial there was ongoing management and monitoring to ensure that the integrity of the
data and the rights and well-being of participants were protected. Monitoring was completed both at site
and at a central level, and regular reports were submitted to relevant parties.Reporting
The trial team were required to submit annual reports on trial progress, data completion rates, and safety
and protocol compliance to the MHRA and MREC; and 6-monthly reports to the funding body [National
Institute for Health Research (NIHR) Health Technology Assessment programme]. Reports were also
prepared for all-trial oversight committees.Site monitoring
On-site monitoring was performed before (prior to recruitment commencing at site), during (after third
patient recruited and then annually) and after recruitment ended at a trial site. Monitors checked the
following during site visits:
l source data verification – data recorded on the CRFs against available source documents
l SAEs/suspected unexpected serious adverse reactions – reported to the sponsor and followed up
to resolution
l resolution of data queries
l investigator site file maintenance
l training records for site staff (3Mg trial specific and GCP) and appropriate delegation of dutiesNIHR Journals Library www.journalslibrary.nihr.ac.uk
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l patient consent procedures
l reporting of protocol deviations/violations.Central data validation
Validation checks were built into the database which enabled validation reports to be generated monthly.
Any missing values, values out of range or inconsistent with the data set were flagged. Queries were sent
to sites and followed up to resolution prior to data lock. Data entry validation was completed on 5% of
CRFs and questionnaires, queries resolved, and database entry error rates reviewed to assess if they were
within acceptable limits.Production of investigational medicinal product
Monitors independent of the study team checked QP-release certificates for all batches of product and
verified that labelling with randomisation number had been done correctly according to the randomisation
number and unblinded kit list.
During the trial we had to change the supplier of the IMPs. Initially the IMPs were supplied by the
pharmacy production unit at RHH. However, this unit did not maintain a MIA licence and subsequently
stopped fully supporting IMP trials during the trial, so we moved production to Tayside Pharmaceuticals.
Labelling and distribution services remained the responsibility of the RHH pharmacy production unit.Changes to the trial protocolAll changes to the trial protocol and study conduct were reviewed by the sponsor and submitted to the
REC and MHRA for approval as appropriate. In summary, the following amendments were made:
l prior to first participant recruitment:
¢ change of sponsor from the University of Sheffield to STH NHS Foundation Trust
¢ option for consent from a legal representative removed, written or oral informed consent must be
obtained, as required by the REC
¢ changes to statistical analysis plan to clarify that the primary analysis incorporated an adjustment
for hospital; clarification that covariate adjusted analysis would be performed; subgroup analysis for
asthma severity to be based on PEFR instead of VAS score (prior to recruitment commencing).
l during trial recruitment:
¢ changes to the number of recruiting sites and list of participating sites/PIs
¢ minor changes to study documents for clarity or administrative purposes
¢ changes to the storage requirements for the IMP, to allow storage at temperatures up to 30 °C
¢ research alert page introduced as a study document to use at sites
¢ IMPD and IB updates
¢ option to telephone patients to collect EQ-5D data if no response from initial and reminder
postal questionnaire
¢ pharmacy production unit changed to Tayside Pharmaceuticals
¢ addition of extra exclusion criteria – patients who have received i.v. or nebulised magnesium
sulphate in the previous 24 hours prior to attendance at the ED
¢ clarification that concomitant medications in SAE reports to be reported only for the period up to
48 hours post IMP administration
¢ extension of recruitment period to 30 June 2012
¢ change from ‘doctors will consent the patient’ to include the option for other health-care
professionals to take consent.17
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METHODS
18ArchivingThe site files and all study documentation were sent to the CTRU and archived according to the sponsor
SOP for a period of 15 years. A log of all documents archived and a list of named individuals who can
access the archive is kept by the CTRU.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22Chapter 3 ResultsTrial progressThe project started on 1 September 2007. Original recruitment predictions were based on the assumption
of 12 hospitals recruiting one patient per centre per week for 2 years, with recruitment complete by the
end of February 2010. The process of setting up the trial took much longer than anticipated and, after the
start of recruitment at the first site, it took a further year until the original target of 12 recruiting sites was
achieved. The main reasons for the delays were (a) slow progress in drawing up contracts between the
sponsor and participating sites; (b) slow progress in securing NHS research governance approval at the
participating sites; and (c) the time taken to provide GCP training for recruiting clinicians. Ethical approval,
by contrast, was secured quickly and efficiently. The need to provide GCP training for emergency
physicians was a specific problem for this trial. Owing to the acuity of the condition, patients could present
to the ED at any time and we aimed to train as many emergency physicians as possible. There appeared to
be no existing NHS infrastructure for supporting trials in emergency medicine, so we developed a GCP
training package that was proportionate to the limited trial activities that the recruiting doctors were
involved with and promoted it through the College of Emergency Medicine.Patient recruitmentThe trial opened to recruitment on 30 July 2008 and closed on 30 June 2012. A total of 1109 participants
were recruited to the trial, 92% of the intended sample size of 1200. Figure 1 shows the number of
patients recruited and the number of recruiting centres open per month, alongside the cumulative
recruitment to the trial. Figure 2 shows the actual recruitment compared with the initial planned
recruitment and subsequent revised recruitment plan.
Recruitment at the participating centres was slower than expected as a result of a combination of a lower
than anticipated availability of eligible patients and difficulties in ensuring that GCP-trained staff were
available to recruit. To address the shortfall in recruitment, we increased the number of sites and
promotional activities. Later in the trial we replaced existing sites that were experiencing recruitment
fatigue or had small numbers of eligible patients with new sites that we identified via the NIHR Injuries and
Emergencies National Priority Group. We were granted a funded extension to the trial to continue
recruitment until 30 June 2012.
Using data available at the time of the funded extension request (after 276 patients were recruited), we
revised the recruitment predictions assuming that we would recruit, on average, 0.4 patients per site per
week and adjusted this for the predicted number of sites that would be recruiting each month. At this
stage, we predicted that we would reach the target number by March 2012. Mid-trial we had to change
the IMP manufacturer, and recruitment to the trial had to be suspended between May and June 2010 as
the new IMPs were not delivered as a result of a problem with the sterile production process. The
seasonality of asthma usually meant that recruitment increased in the winter months, but the final winter
season saw generally lower numbers of presenting patients. We kept a large proportion of the sites open
to recruitment for an additional 3 months compared with the revised recruitment plan, staggering the
close of sites to assist with scheduling close-out monitoring.19
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RESULTS
22Non-recruited patientsDuring the trial we asked participating centres to record basic anonymised details of patients attending ED
aged 16 years or over with acute severe asthma who were not recruited. These data were captured by a
mixture of prospective screening by recruiting doctors and retrospective case note review by research
nurses. Unfortunately, limited research nurse availability and service pressure in the ED prevented reliable
collection of these data at some centres. Nevertheless, data were collected from a total of 3948
non-recruited patients attending at recruiting centres during the trial. Of these, 1165 patients were not
identified by recruiting doctors because of a variety of administrative reasons (the ED was too busy, no
GCP-trained doctors were available or no treatment packs were available) but were retrospectively
identified by research nurses on the basis of information in the ED record. The remaining 2783 patients
were identified prospectively, but excluded on the basis of ineligibility (n = 847), declining to participate
(n = 200), inability to give consent (n = 21), administrative reasons as outlined above (n = 306) and other
reasons (n = 201), while no reason was recorded for 89 patients. The patient characteristics recorded (age
and sex) were not obviously different between those who did not take part and those who did (Table 4),
with the possible exception of the subset who were eligible but unable to give consent.The trial populationThe CONSORT flow chart (Figure 3) shows the flow of participants through the trial. Of the 1109
participants randomised, 25 were excluded from the analysis. Eleven patients received no medication and
no data were collected after randomisation. These patients either withdrew consent prior to any
medication being delivered or recruiting doctors had randomised them before taking consent and patients
subsequently refused consent. Two patients self-discharged without being treated. There were nine
occasions where the numbered medication pack was not available in the ED and no treatment was
subsequently given. The remaining three patients received treatment but there were protocol violations
and these patients should not have been recruited: two were subsequently found to be previous
participants and one was a prisoner. All remaining 1084 patients were included in analyses according to
intention-to-treat principles, regardless of whether or not they received any medication.
Protocol deviations which did not result in the participants being removed from analysis were also reported
and reviewed at PMG meetings. A total of 203 protocol deviations were reported, which can be broadly
categorised as follows: 42 deviations from the trial treatment protocol (randomised but trial treatment not
commenced, treatment started but not completed or incorrect treatment), 143 consent not fully
documented (no witness signature, verbal but not written consent, consent taken by a doctor without
GCP training and/or not on delegation, log or tick boxes not completed), 15 administrative errorsTABLE 4 Non-recruited patients
Patient classification Age (years), mean (SD) Sex, n (%) male
Recruited (N = 1109) 36 (14) 321 (30)
Not identified (N = 1165) 36 (16) 359 (31)
Ineligible (N = 847) 37 (15) 217 (26)
Declined to participate (N = 200) 37 (16) 62 (31)
Unable to give consent (N = 31) 44 (19) 11 (36)
Administrative reasons (N = 306) 37 (15) 94 (31)
Other (N = 201) 38 (17) 50 (25)
Not recorded (N = 89) 35 (18) 30 (33)
SD, standard deviation.
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Enrolment
Excluded (n = 1674)
•
 -
 -
 -
 -
•
•
•
•
•
Ineligible (n = 847)
  Life-threatening asthma
  (n = 466)
  Contraindicated (n = 73)
  Received magnesium sulphate
  in previous 24 hours (n = 19)
  Previous participant (n = 319)
Declined to participate (n = 200)
Administrative reasons (ED too
busy, staff not trained no
IMP available; n = 306)
Unable to give consent (n = 31)
Other reasons (n = 201)
Not recorded (n = 89)
Randomised (n = 1109)
Assessed for eligibility (n = 2783)
Allocated nebulised magnesium
sulphate (n = 339)
• Received intervention (n = 333)
• Did not receive intervention (n = 6)
Withdrew consent prior to treatment
(n = 2)
Treatment pack not available (n = 4)
Allocated to i.v. magnesium sulphate
(n = 406)
• Received allocated intervention
   (n = 396)
• Did not receive intervention (n = 10)
Withdrew consent prior to treatment
(n = 7)
Treatment pack not available (n = 2)
Allocated to placebo (n = 364)
• Received allocated intervention
   (n = 358)
• Did not receive intervention (n = 6)
Withdrew consent prior to treatment
(n = 2)
Treatment pack not available (n = 3)
Allocation
Analysed (n = 332)
•  Excluded from analysis (n = 7)
Treatment not started (n = 6)
Ineligible patient, prisoner (n = 1)
Completed follow-up in ED (n = 332)
30-day questionnaire completed
(n = 152)
Completed follow-up in ED (n = 393)
30-day questionnaire completed
(n = 186)
Completed follow-up in ED (n = 357)
30-day questionnaire completed
(n = 162)
Analysed (n = 394)
•  Excluded from analysis (n = 12)
Treatment not started (n = 10)
Ineligible patient, previous
participant (n = 2)
Analysed (n = 358)
•  Excluded from analysis (n = 6)
Treatment not started (n = 6)
Follow-up
Analysis
Self-discharged prior to treatment
(n = 1)
Self-discharged prior to treatment
(n = 1)
FIGURE 3 The CONSORT flow chart.
DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22
23
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
RESULTS
24(prescription incorrectly completed, patient details recorded incorrectly, randomisation after treatment
commenced or pack opened in error), and three screening assessment queries. The apparently high
number of deviations can be attributed to the complexities of recruiting in an emergency setting and our
requirement for sites to report any deviation from the protocol, however minor. Deviations from the
consent procedure were reviewed to ensure that there was sufficient evidence that consent had been
obtained before deciding if the participant should remain in the trial.
Table 5 summarises the recruitment and allocation of patients across the centres. Overall, 34 centres
recruited to the study, of which 24 recruited 10 or more patients. The remaining centres were combined
into one group for the purposes of all analyses. Table 6 shows the demographics and characteristics of theTABLE 5 Recruitment and allocation across trial centres
Centre
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Royal Infirmary of
Edinburgh
56 (17%) 67 (17%) 56 (16%) 179 (17%)
Sheffield – Northern
General Hospital
30 (9%) 41 (10%) 35 (10%) 106 (10%)
Royal United Hospital Bath 25 (8%) 29 (7%) 23 (6%) 77 (7%)
Aberdeen Royal Infirmary 17 (5%) 23 (6%) 17 (5%) 57 (5%)
University Hospital of
N. Staffordshire
20 (6%) 17 (4%) 20 (6%) 57 (5%)
Crosshouse Hospital 18 (5%) 15 (4%) 19 (5%) 52 (5%)
Bristol Frenchay Hospital 13 (4%) 17 (4%) 18 (5%) 48 (4%)
Barnsley Hospital 14 (4%) 14 (4%) 18 (5%) 46 (4%)
Plymouth – Derriford
Hospital
12 (4%) 14 (4%) 12 (3%) 38 (4%)
York Hospital 10 (3%) 15 (4%) 13 (4%) 38 (4%)
Ayr Hospital 9 (3%) 12 (3%) 10 (3%) 31 (3%)
Royal Devon and Exeter
Hospital
12 (4%) 8 (2%) 11 (3%) 31 (3%)
Bristol Royal Infirmary 10 (3%) 11 (3%) 9 (3%) 30 (3%)
Leicester Royal Infirmary 9 (3%) 7 (2%) 14 (4%) 30 (3%)
Kettering General Hospital 9 (3%) 10 (3%) 10 (3%) 29 (3%)
Lancaster Royal Infirmary 8 (2%) 16 (4%) 5 (1%) 29 (3%)
Derbyshire Royal Infirmary 6 (2%) 11 (3%) 11 (3%) 28 (3%)
Fife – Queen Margaret
Hospital
5 (2%) 11 (3%) 10 (3%) 26 (2%)
Hull Royal Infirmary 10 (3%) 9 (2%) 4 (1%) 23 (2%)
Royal Alexandra Hospital –
Paisley
7 (2%) 8 (2%) 6 (2%) 21 (2%)
University Hospital
Coventry
5 (2%) 7 (2%) 7 (2%) 19 (2%)
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TABLE 5 Recruitment and allocation across trial centres (continued )
Centre
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Fife – Victoria Hospital 5 (2%) 5 (1%) 5 (1%) 15 (1%)
Addenbrookes Hospital,
Cambridge
3 (1%) 6 (2%) 4 (1%) 13 (1%)
The Royal London Hospital 3 (1%) 4 (1%) 4 (1%) 11 (1%)
Southend University
Hospital
4 (1%) 2 (1%) 3 (1%) 9 (1%)
James Cook University
Hospital – Middlesbrough
3 (1%) 3 (1%) 1 (< 1%) 7 (1%)
Hairmyres Hospital 2 (1%) 3 (1%) 2 (1%) 7 (1%)
Leeds Teaching Hospitals 1 (< 1%) 1 (< 1%) 3 (1%) 5 (< 1%)
Northampton General
Hospital
1 (< 1%) 1 (< 1%) 3 (1%) 5 (< 1%)
Rotherham General
Hospital
2 (1%) 3 (1%) 0 5 (< 1%)
Doncaster Royal Infirmary 0 3 (1%) 1 (< 1%) 4 (< 1%)
Bradford Royal Infirmary 1 (< 1%) 0 2 (1%) 3 (< 1%)
Queens Medical Centre,
Nottingham
1 (< 1%) 1 (< 1%) 1 (< 1%) 3 (< 1%)
Pinderfields Hospital 1 (< 1%) 0 1 (< 1%) 2 (< 1%)
Values in brackets denote per cent of total.
TABLE 6 Patient demographics and characteristics
Patient
characteristic
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Age (years)
Mean (SD) 36.5 (14.8) 35.6 (13.1) 36.4 (14.1) 36.1 (14.0)
Median (IQR) 35.0 (23–47) 34.0 (25–44) 34.5 (24–47) 34.0 (24–46)
Min., max. 16, 85 16, 84 16, 88 16, 88
Sexa
Male 100 (30%) 115 (29%) 106 (30%) 321 (30%)
Female 232 (70%) 279 (71%) 252 (70%) 763 (70%)
Ethnicitya
White 286 (86%) 369 (94%) 319 (89%) 974 (90%)
Mixed 2 (1%) 1 (< 1%) 5 (1%) 8 (1%)
Asian or Asian British 14 (4%) 8 (2%) 16 (4%) 38 (4%)
Black or black British 2 (1%) 5 (1%) 4 (1%) 11 (1%)
Other 2 (1%) 0 0 2 (< 1%)
Not stated 22 (7%) 8 (2%) 11 (3%) 41 (4%)
Missing 4 (1%) 3 (1%) 3 (1%) 10 (1%)
continued
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TABLE 6 Patient demographics and characteristics (continued )
Patient
characteristic
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Smoking statusa
Never 151 (45%) 156 (40%) 143 (40%) 450 (42%)
Current 98 (30%) 138 (35%) 127 (35%) 363 (33%)
Previous 72 (22%) 95 (24%) 81 (23%) 248 (23%)
Missing 11 (3%) 5 (1%) 7 (2%) 23 (2%)
Predicted PEFR
n 324 389 346 1059
Mean (SD) 430.0 (118.8) 431.8 (116.9) 435.0 (110.8) 432.3 (115.4)
Median (IQR) 425.0 (350–500) 435.0 (350–500) 425.0 (350–500) 425.0 (350–500)
Min., max. 100, 700 140, 800 150, 790 100, 800
Previous admissions with asthma
At least one previous
ITU admissiona
56 (17%) 61 (15%) 39 (11%) 156 (14%)
At least one previous
admissiona
226 (68%) 260 (66%) 213 (59%) 699 (64%)
If yes, time since last admission with asthma (months)
n 221 256 208 688
Mean (SD) 42.0 (72.2) 38.5 (69.5) 40.8 (61.9) 40.1 (68.0)
Median (IQR) 12.0 (4–47) 12.0 (4–37) 17.0 (6–48) 12.5 (4–47)
Min., max. 3 days, 32 years 1 day, 50 years 1 day, 40 years 1 day, 50 years
Entry criterion for acute severe asthmaa,b
PEFR < 50% of best or
predicted
179 (54%) 205 (52%) 192 (53%) 576 (53%)
Heart rate > 110 beats
per minute
213 (64%) 251 (64%) 218 (61%) 682 (63%)
Respiratory rate > 25
breaths per minute
178 (54%) 227 (58%) 204 (57%) 609 (67%)
Unable to complete
sentences in one breath
138 (42%) 159 (40%) 139 (39%) 436 (40%)
Baseline PEFRa
< 33% predicted 53 (16%) 50 (13%) 56 (16%) 156 (15%)
33–50% predicted 112 (34%) 116 (29%) 116 (32%) 344 (32%)
50–75% predicted 107 (32%) 148 (38%) 118 (33%) 373 (34%)
≥ 75% predicted 36 (11%) 61 (15%) 37 (10%) 134 (12%)
Not recorded 24 (7%) 19 (5%) 31 (9%) 74 (7%)
IQR, interquartile range; max., maximum; min., minimum; SD, standard deviation.
a Value in brackets denotes per cent of total.
b More than one may apply.
RESULTS
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DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22trial population. PEFR values reported in this table are predicted values. The actual baseline values are
reported alongside the 1- and 2-hour values in Table 25. Patients were generally female (70%), white
(90%) and relatively young (82% were below the age of 50 years). Overall, 64% of patients had
previously been admitted to hospital for asthma, with the percentage being higher in the active two arms
(68% nebulised, 66% i.v. and 59% placebo) and 14% of patients had previously been admitted to ITU.
Where previous admissions had been recorded, around half had been admitted in the past year.Trial and other treatments givenTable 7 shows the concurrent medications given in the 24 hours prior to hospital attendance, in the
ambulance and ED immediately prior to randomisation, and alongside trial treatments in the 4 hours
immediately after randomisation. Most patients (88%) had used salbutamol in the 24 hours prior to
attendance and one-third had taken prednisolone. Use of salbutamol (95%) and ipratropium bromide
(72%) was typical in the ambulance or ED prior to randomisation, whereas 41% were given prednisolone
and 21% hydrocortisone. Salbutamol, ipratropium bromide, prednisolone and hydrocortisone were also
commonly given alongside trial treatments.
Table 8 shows the proportion of patients receiving prednisolone or hydrocortisone at any point from
24 hours before attendance to 4 hours after randomisation. Around one-third of patients had taken
corticosteroids in the 24 hours before attendance, 61% were given corticosteroids before randomisation
and 21% after. Some patients were given additional corticosteroids in the ambulance or ED despite
having taken corticosteroids in the previous 24 hours and, therefore, overall 95% of the trial population
received corticosteroid therapy at some point from 24 hours prior to hospital attendance to 4 hours
after randomisation. Table 9 shows the total dose of salbutamol given in the ambulance or ED prior to
randomisation or up to 4 hours after randomisation. All but 10 patients (1%) received salbutamol at some
point and 95% received salbutamol prior to randomisation, with a mean dose of 4.9 mg. Overall, it
appears that there was adherence to BTS/SIGN guidance and substantial use of standard treatments that
are known to be effective.2
Three patients (all in the placebo group) were given i.v. magnesium sulphate in the ED or ambulance prior
to randomisation. After these cases were identified, the protocol was amended to exclude patients who
had received magnesium sulphate in the 24 hours prior to randomisation. A further 58 patients (5%)
received i.v. magnesium sulphate after randomisation as a result of the treating physician deciding that the
patient’s response to initial treatment suggested that they were no longer in equipoise. These cases were
evenly distributed across the three groups.
Table 10 shows the trial medications received by the three groups. Most patients (89%) received the full
i.v. infusion and only 2% received less than half. Similarly, most patients (99%) received all three
nebulisers and a substantial proportion of the nebuliser solution.27
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TABLE 7 Medication usage prior to attendance, during and after treatment
Medication Usage
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Used medication 24 hours prior
to attendance
304 (92%) 370 (94%) 320 (89%) 994 (92%)
Salbutamol 293 (88%) 350 (89%) 309 (86%) 952 (88%)
Prednisolone 115 (35%) 140 (36%) 106 (30%) 361 (33%)
Seretide 58 (17%) 54 (14%) 62 (17%) 174 (16%)
Ipratropium bromide 42 (13%) 58 (15%) 47 (13%) 147 (14%)
Pulmicort 32 (10%) 33 (8%) 24 (7%) 89 (8%)
Beclometasone (Clenil) 25 (8%) 23 (6%) 22 (6%) 70 (6%)
Montelukast 15 (5%) 12 (3%) 14 (4%) 41 (4%)
Amoxicillin 9 (3%) 13 (3%) 12 (3%) 34 (3%)
Salmeterol (Serevent) 12 (4%) 10 (3%) 7 (2%) 29 (3%)
Terbutaline (Bricanyl) 8 (2%) 9 (2%) 8 (2%) 25 (2%)
Theophylline 8 (2%) 7 (2%) 7 (2%) 22 (2%)
Tiotropium (Spiriva) 7 (2%) 5 (1%) 7 (2%) 19 (2%)
Hydrocortisone 6 (2%) 5 (1%) 4 (1%) 15 (1%)
Aminophylline 7 (2%) 4 (1%) 3 (1%) 14 (1%)
Formoterol (Oxis®, AstraZeneca
UK Ltd)
5 (2%) 1 (< 1%) 0 6 (1%)
Clarithromycin 2 (1%) 1 (< 1%) 0 3 (< 1%)
Combivent 0 2 (1%) 1 (< 1%) 3 (< 1%)
Zarfirlukast 2 (1%) 0 1 (< 1%) 3 (< 1%)
Other 5 (2%) 4 (1%) 6 (2%) 15 (1%)
Given medication in ambulance
or ED prerandomisation
325 (98%) 375 (95%) 344 (96%) 1044 (96%)
Salbutamol 320 (96%) 367 (93%) 338 (94%) 1025 (95%)
Ipratropium bromide 241 (73%) 279 (71%) 259 (72%) 779 (72%)
Prednisolone 126 (38%) 154 (39%) 168 (47%) 448 (41%)
Hydrocortisone 71 (21%) 86 (22%) 69 (19%) 226 (21%)
Combivent 9 (3%) 19 (5%) 10 (3%) 38 (4%)
Amoxicillin 7 (2%) 3 (1%) 3 (1%) 13 (1%)
Amoxicillin trihydrate/
potassium clavulanate
(Augmentin®, GlaxoSmithKline
UK)
2 (1%) 5 (1%) 2 (1%) 9 (1%)
RESULTS
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TABLE 7 Medication usage prior to attendance, during and after treatment (continued )
Medication Usage
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Clarithromycin 1 (<1%) 2 (1%) 4 (1%) 7 (1%)
Aminophylline 2 (1%) 1 (< 1%) 0 3 (< 1%)
Magnesium sulphate 0 0 3 (1%) 3 (< 1%)
Theophylline 0 1 (< 1%) 1 (< 1%) 2 (< 1%)
Montelukast 0 1 (< 1%) 0 1 (< 1%)
Pulmicort 0 0 1 (< 1%) 1 (< 1%)
Other 2 (1%) 0 0 2 (< 1%)
Given medication 0–4 hours post
randomisation
180 (54%) 195 (49%) 182 (51%) 557 (51%)
Salbutamol 107 (32%) 101 (26%) 93 (26%) 301 (28%)
Prednisolone 64 (19%) 62 (16%) 54 (15%) 180 (17%)
Ipratropium bromide 59 (18%) 50 (13%) 53 (15%) 162 (15%)
Hydrocortisone 16 (5%) 25 (6%) 19 (5%) 60 (6%)
Magnesium sulphate 21 (6%) 16 (4%) 21 (6%) 58 (5%)
Amoxicillin 9 (3%) 16 (4%) 15 (4%) 40 (4%)
Augmentin 11 (3%) 12 (3%) 7 (2%) 30 (3%)
Combivent 7 (2%) 13 (3%) 7 (2%) 27 (2%)
Clarithromycin 7 (2%) 9 (2%) 9 (3%) 25 (2%)
Aminophylline 8 (2%) 7 (2%) 9 (3%) 24 (2%)
Pulmicort 2 (1%) 3 (1%) 1 (< 1%) 6 (1%)
Seretide 0 1 (< 1%) 1 (< 1%) 2 (< 1%)
Theophylline 1 (< 1%) 1 (< 1%) 0 2 (< 1%)
Other 9 (3%) 3 (1%) 3 (1%) 15 (1%)
Values in brackets denote per cent of total.
TABLE 8 Hydrocortisone or prednisolone usage
Usage
Nebulised magnesium
(n = 332)
Intravenous magnesium
(n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Any usage in or before ED 316 (95%) 372 (94%) 344 (96%) 1032 (95%)
Last 24 hours before
attendance
119 (36%) 143 (36%) 110 (31%) 372 (34%)
Ambulance/ED pre
randomisation
191 (58%) 236 (60%) 231 (65%) 658 (61%)
After randomisation 0–4 hours 77 (23%) 83 (21%) 69 (19%) 229 (21%)
Values in brackets denote per cent of total.
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TABLE 10 Trial medications received
Medication received
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Total volume of i.v. infusion (ml)
Mean (SD) 97.2 (14.8) 96.5 (16.1) 97.9 (12.7) 97.1 (14.6)
100a 299 (90%) 349 (89%) 320 (89%) 968 (89%)
90–99.9a 11 (3%) 18 (5%) 16 (4%) 45 (4%)
70–89.9a 8 (2%) 8 (2%) 4 (1%) 20 (2%)
50–69.9a 0 2 (1%) 1 (< 1%) 3 (< 1%)
0–49.9a 7 (2%) 11 (3%) 6 (2%) 24 (2%)
Missinga 7 (2%) 6 (2%) 11 (3%) 24 (2%)
Number of nebulisers given
0 0 0 0 0
1a 2 (1%) 4 (1%) 0 6 (1%)
2a 5 (2%) 1 (< 1%) 2 (1%) 8 (1%)
3a 323 (98%) 387 (99%) 355 (99%) 1065 (99%)
Missinga 2 2 1 5
Total volume of nebuliser excluding salbutamol (ml)
Mean (SD) 21.0 (4.1) 21.5 (3.9) 21.5 (3.6) 21.3 (3.9)
22.5a 261 (79%) 349 (89%) 307 (86%) 917 (85%)
20–22.4a 11 (3%) 7 (2%) 8 (2%) 26 (2%)
15–19.9a 21 (6%) 12 (3%) 18 (5%) 51 (5%)
7.5–14.9a 18 (5%) 9 (2%) 9 (3%) 36 (3%)
0–7.4a 5 (2%) 9 (2%) 6 (2%) 20 (2%)
Missinga 16 (5%) 8 (2%) 10 (3%) 34 (3%)
SD, standard deviation.
a Values in brackets denote per cent of total.
TABLE 9 Salbutamol dosage
Usage
Nebulised magnesium
(n = 332)
Intravenous magnesium
(n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Usage in ambulance or ED
Any usagea 329 (99%) 391 (99%) 354 (99%) 1074 (99%)
Mean (SD) dose given (mg) 8.7 (3.4) 8.0 (3.4) 8.2 (3.4) 8.3 (3.4)
Prerandomisation usage (ambulance or ED)
Any usagea 320 (96%) 367 (93%) 338 (94%) 1025 (95%)
Mean (SD) dose given (mg) 5.0 (1.3) 4.8 (1.5) 4.9 (1.4) 4.9 (1.4)
Post-randomisation usage in ED
Any usagea 232 (70%) 243 (62%) 232 (65%) 707 (65%)
Mean (SD) dose given (mg) 3.8 (3.4) 3.3 (3.3) 3.4 (3.2) 3.4 (3.3)
SD, standard deviation.
a Values in brackets denote per cent of total.
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Table 11 shows the primary, service-orientated outcome, namely admission to hospital at presentation
or within 1 week of presentation. Overall, 827 out of 1084 (76%) of patients were admitted to
hospital within 1 week: 811 were admitted at initial attendance, 14 were initially discharged but were
admitted within the next week, and the status of two patients was unknown and, therefore, the patients
were analysed as having been admitted. The percentage admitted was lowest in the i.v. magnesium
sulphate group (72%) but similar in the placebo (78%) and nebulised magnesium sulphate (79%) groups.
None of the contrasts or pairwise comparisons was statistically significant at the 5% level. These findings
were also borne out in the per-protocol subset, which showed very similar results (Table 12).TABLE 11 Admission to hospital at presentation or within 1 week
Classification
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Status at 4 hours
Admitteda 254 (77%) 279 (71%) 278 (78%) 811 (75%)
Dischargeda 77 (23%) 114 (29%) 80 (22%) 271 (25%)
Dead 0 0 0 0
Unknowna 1 (< 1%) 1 (< 1%) 0 2 (< 1%)
Subsequent hospital
admission within 7 daysa
15 (5%) 10 (3%) 7 (2%) 32 (3%)
Subsequent hospital
admission following
discharge at initial
attendancea
6 (2%) 5 (1%) 3 (1%) 14 (1%)
Admitted to hospital at any
time within 7 daysa
261 (79%) 285 (72%) 281 (78%) 827 (76%)
Comparisons Odds ratio (95% CI) p-value
Active vs. placebo 0.84 (0.61 to 1.15) 0.276
i.v. vs. nebuliser 0.76 (0.53 to 1.10) 0.146
i.v. vs. placebo 0.73 (0.51 to 1.04) 0.083
Nebuliser vs. placebo 0.96 (0.65 to 1.40) 0.819
a Values in brackets denote per cent of total.
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TABLE 12 Admission to hospital at presentation or within 1 week, per protocol
Classification
Nebulised magnesium
sulphate (n = 305)
Intravenous magnesium
sulphate (n = 368)
Placebo
(n = 333)
Total
(n = 1006)
Status at 4 hours
Admitteda 236 (77%) 263 (71%) 258 (77%) 757 (75%)
Dischargeda 69 (23%) 105 (29%) 75 (23%) 249 (25%)
Dead 0 0 0 0
Unknown 0 0 0 0
Subsequent hospital admission
within 7 daysa
14 (5%) 8 (2%) 7 (2%) 29 (3%)
Subsequent hospital admission
following discharge at initial
attendancea
6 (2%) 4 (1%) 3 (1%) 13 (1%)
Admitted to hospital at any time
within 7 daysa
242 (79%) 267 (73%) 261 (78%) 770 (77%)
Comparisons Odds ratio (95% CI) p-value
Active vs. placebo 0.85 (0.61 to 1.19) 0.348
i.v. vs. nebuliser 0.78 (0.54 to 1.15) 0.210
i.v. vs. placebo 0.75 (0.52 to 1.09) 0.133
Nebuliser vs. placebo 0.96 (0.64 to 1.44) 0.848
a Values in brackets denote per cent of total.
RESULTS
32Patient breathlessness is summarised in Tables 13 (complete case), 14 (complete case, per-protocol) and
15 (imputed). The complete case analysis is also presented graphically in Figure 4. The change in VAS at
2 hours was recorded in 976 out of 1084 (90%) members of the cohort. Improvements in breathlessness
were observed in all three groups. In the complete case data, the mean change from baseline was largest
[34.3 mm; standard deviation (SD) 27.7 mm] in the i.v. group and smallest (28.2 mm; SD 27.4 mm) in the
nebulised group, whereas the change in the placebo group was between the two (31.3 mm; SD 29.4 mm).
Overall, magnesium sulphate did not reduce breathlessness (mean difference = 0mm, 95% CI –1.9 to
1.9 mm; p = 0.999). Although i.v. magnesium sulphate appeared superior to nebulised magnesium
sulphate (mean difference = 5.1 mm; 95% CI 0.8 to 9.4 mm; p = 0.019), the magnitude of the difference
in clinical terms is small. The post-hoc comparison of i.v. magnesium sulphate against placebo yielded no
significant difference (mean difference 2.6 mm; 95% CI –1.6 to 6.8 mm; p = 0.231), although this may be
partly due to a small imbalance at baseline, as the pretreatment VAS scores were slightly higher in the
placebo group than in the i.v. group. Nonetheless, the magnitude of difference between i.v. and placebo
is minor when considered in the context that the minimum clinically significant difference for VAS
breathlessness has been estimated to be 22mm.48NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 13 Visual analogue scale (mm) – complete case
Measurement
Nebulised magnesium
(n = 332)
Intravenous magnesium
(n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
VAS at baseline
Number of
observations
326 386 349 1061
Mean [mm (SD)] 61.6 (23.3) 61.9 (22.8) 63.1 (23.5) 62.2 (23.2)
Median [mm (IQR)] 65.0 (46–80) 65.0 (46–80) 69.0 (46–82) 67.0 (46–80)
Min., max. (mm) 2, 100 4, 100 0, 100 0, 100
VAS at 1 hour
Number of
observations
314 372 344 1030
Mean [mm (SD)] 42.9 (25.7) 37.7 (25.4) 41.9 (25.0) 40.7 (25.4)
Median [mm (IQR)] 42.5 (23–63) 34.5 (16–58) 41.0 (20–62) 39.0 (19–60)
Min., max. (mm) 0, 100 0, 98 0, 99 0, 100
Change in VAS at 1 hour
Number of
observations
314 372 344 1030
Mean [mm (SD)] –18.4 (22.8) –24.2 (24.4) –21.5 (24.7) –21.5 (24.1)
Median [mm (IQR)] –15.0 (–32 to –4) –20.0 (–40 to –7) –17.0 (–37 to –5) –18.0 (–35 to –5)
Min., max. (mm) –86, 63 –96, 39 –93, 60 –96, 63
VAS at 2 hours
Number of
observations
296 357 323 976
Mean [mm (SD)] 32.9 (27.8) 27.7 (26.4) 32.4 (27.5) 30.8 (27.3)
Median [mm (IQR)] 27.5 (8–53) 18.0 (5–45) 25.0 (9–53) 23.0 (7–52)
Min., max. (mm) 0, 99 0, 100 0, 100 0, 100
Change in VAS at 2 hours
Number of
observations
296 357 323 976
Mean [mm (SD)] –28.2 (27.4) –34.3 (27.7) –31.3 (29.4) –31.5 (28.2)
Median [mm (IQR)] –28.0 (–47 to –9) –33.0 (–53 to –14) –29.0 (–53 to –10) –30.0 (–52 to –11)
Min., max. (mm) –94, 90 –99, 45 –98, 63 –99, 90
Comparisons Mean difference (95% CI) p-value
Active vs. placebo 0.0 (–1.9 to 1.9) 0.999
i.v. vs. nebuliser –5.1 (–9.4 to –0.8) 0.019
i.v. vs. placebo –2.6 (–6.8 to 1.6) 0.231
Nebuliser vs.
placebo
2.6 (–1.8 to 7.0) 0.253
IQR, interquartile range; max., maximum; min., minimum.
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TABLE 14 Visual analogue scale (mm) – complete case, per protocol
Measurement
Nebulised magnesium
(n = 305)
Intravenous magnesium
(n = 368)
Placebo
(n = 333)
Overall
(n = 1006)
VAS at baseline
Number of
observations
303 362 326 991
Mean [mm (SD)] 61.7 (23.3) 61.6 (22.7) 63.0 (23.5) 62.1 (23.1)
Median [mm (IQR)] 65.0 (46–80) 65.0 (47–80) 69.0 (45–82) 66.0 (46–80)
Min., max. (mm) 2, 100 4, 100 0, 100 0, 100
VAS at 1 hour
Number of
observations
297 354 322 973
Mean [mm (SD)] 43.6 (25.7) 37.9 (25.7) 42.0 (25.0) 41.0 (25.5)
Median [mm (IQR)] 43.0 (24–64) 34.5 (16–59) 41.0 (20–62) 39.0 (19–61)
Min., max. (mm) 0, 100 0, 98 0, 99 0, 100
Change in VAS at 1 hour
Number of
observations
297 354 322 973
Mean [mm (SD)] –17.9 (22.2) –23.8 (24.2) –21.3 (24.5) –21.2 (23.8)
Median [mm (IQR)] –15.0 (–30 to –3) –19.5 (–39 to –7) –17.0 (–37 to –5) –17.0 (–34 to –5)
Min., max. (mm) –86, 63 –96, 39 –93, 60 –96, 63
VAS at 2 hours
Number of
observations
280 341 304 925
Mean [mm (SD)] 33.7 (27.8) 28.0 (26.6) 32.7 (27.7) 31.3 (27.4)
Median [mm (IQR)] 28.5 (10–54) 18.0 (5–45) 25.5 (10–53) 24.0 (7–52)
Min., max. (mm) 0, 99 0, 100 0, 100 0, 100
Change in VAS at 2 hours
Number of
observations
280 341 304 925
Mean [mm (SD)] –27.7 (27.1) –34.0 (27.7) –31.1 (29.4) –31.1 (28.2)
Median [mm (IQR)] –27.5 (–46 to –9) –33.0 (–52 to –14) –28.5 (–53 to –10) –30.0 (–51 to –11)
Min., max. (mm) –88, 90 –99, 45 –98, 63 –99, 90
Comparisons Mean difference (95% CI) p-value
Active vs. placebo 0.1 (–1.8 to 2.0) 0.950
i.v. vs. nebuliser –5.2 (–9.6 to –0.8) 0.021
i.v. vs. placebo –2.5 (–6.8 to 1.8) 0.261
Nebuliser vs. placebo 2.6 (–1.8 to 7.0) 0.253
IQR, interquartile range; max., maximum; min., minimum.
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TABLE 15 Visual analogue scale (mm) – results from different imputation strategies
Imputation strategy
Number of
participants included
Mean difference
(95% CI) p-value
Active vs. placebo
ITT, no imputation 976 0.0 (–1.9 to 1.9) 0.999
ITT, linear interpolation 981 0.1 (–1.7 to 1.9) 0.956
ITT, multiple imputation 1084 –1.0 (–2.3 to 4.3) 0.549
PP, no imputation 925 0.1 (–1.8 to 2.0) 0.950
i.v. vs. nebuliser
ITT, no imputation 976 –5.1 (–9.4 to –0.8) 0.019
ITT, linear interpolation 981 –4.8 (–9.0 to –0.5) 0.027
ITT, multiple imputation 1084 –5.2 (–9.1 to 1.3) 0.007
PP, no imputation 925 –5.2 (–9.6 to –0.8) 0.021
i.v. vs. placebo
ITT, no imputation 976 –2.6 (–6.8 to 1.6) 0.231
ITT, linear interpolation 981 –2.3 (–6.4 to 1.9) 0.279
ITT, multiple imputation 1084 –3.6 (–7.3 to 0.1) 0.059
PP, no imputation 925 –2.5 (–6.8 to 1.8) 0.261
Nebuliser vs. placebo
ITT, no imputation 976 2.6 (–1.8 to 7.0) 0.253
ITT, linear interpolation 981 2.5 (–1.9 to 6.9) 0.261
ITT, multiple imputation 1084 1.6 (–2.2 to 5.5) 0.401
PP, no imputation 925 2.6 (–1.8 to 7.0) 0.253
ITT, intention to treat; PP, per protocol.
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FIGURE 4 Change in VAS breathlessness (complete case analysis). Neb, nebuliser; Pla, placebo.
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RESULTS
36Secondary outcome analysis
Table 16 and Figure 5 compare the hospital length of stay after initial attendance for the three groups.
The length of stay was not recorded unless the patients had been admitted; these patients are represented
by the ‘spike’ at 3.9 hours in the Kaplan–Meier graph. The length of stay was shorter in the i.v. group,
although not significantly so.
Table 17 shows the number of days spent on ICU, HDU and a general medical ward up to 30 days after
recruitment. Only 2% of the cohort spent any days on ICU and only 6% spent any days on HDU. There
were no significant differences between the three groups in the number of days spent in any location.
Table 18 shows the number of patients requiring invasive or non-invasive ventilatory support. Only 1%
of the cohort required ventilatory support and there were no significant differences between the
three groups.TABLE 16 Length of stay
Measurement/
classification
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Time to dischargea
Time not known 3 (1%) 6 (2%) 5 (1%) 14 (1%)
Patient died 1 (< 1%) 1 (< 1%) 0 2 (< 1%)
Patient admitted,
duration not known
1 (< 1%) 2 (1%) 4 (1%) 7 (1%)
Nothing recorded 1 (< 1%) 3 (1%) 1 (< 1%) 5 (< 1%)
Time recorded
n 329 388 353 1070
Mean [hours (SD)] 63.2 (79.7) 57.0 (75.1) 63.3 (84.3) 61.0 (79.6)
Median [hours (IQR)] 35.1 (5–88) 31.5 (4–78) 36.4 (5–87) 34.1 (4–84)
Min., max. (hours) 3, 623 4, 723 1, 694 1, 723
Not admitted/
discharged within
4 hoursa
80 (24%) 120 (30%) 83 (23%) 283 (26%)
4–6 hoursa 4 (1%) 11 (3%) 8 (2%) 23 (2%)
6–12 hoursa 16 (5%) 10 (3%) 15 (4%) 41 (4%)
12–24 hoursa 33 (10%) 34 (9%) 38 (11%) 105 (10%)
> 24 hoursa 196 (59%) 213 (54%) 209 (58%) 618 (57%)
Comparisons Time ratio (95% CI) p-value
Active vs. placebo 0.92 (0.76 to 1.13) 0.432
i.v. vs. nebuliser 0.87 (0.69 to 1.09) 0.230
i.v. vs. placebo 0.86 (0.69 to 1.08) 0.192
Nebuliser vs. placebo 0.99 (0.78 to 1.25) 0.936
IQR, interquartile range; max., maximum; min., minimum.
a Values in brackets denote per cent of total.
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TABLE 17 Number of days on ICU, HDU or ward
Measurement
Nebulised
magnesium
sulphate
(n = 332)
Intravenous
magnesium
sulphate
(n = 394)
Placebo
(n = 358)
Total
(n = 1084)
p-values
Active vs.
placebo
Intravenous
vs. nebuliser
Days in hospital at any location
Number (%) with
any staya
253 (76) 278 (71) 267 (75) 798 (74) 0.613 0.087
Mean [days (SD)] 3.3 (4.8) 3.1 (5.0) 2.9 (3.9) 3.1 (4.6)
Median [days (IQR)]b 2.0 (1–4) 2.0 (0–4) 2.0 (0–4) 2.0 (0–4) 0.598 0.218
Days on ICU
Number (%) with
any ICU staya
9 (3) 11 (3) 5 (1) 25 (2) 0.161 0.947
Mean [days (SD)] 3.3 (4.8) 3.1 (5.0) 2.9 (3.9) 3.1 (4.6)
Median [days (IQR)]b 2.0 (1–4) 2.0 (0–4) 2.0 (0–4) 2.0 (0–4) 0.159 0.941
Days on HDU
Number (%) with
any HDU staya
22 (7) 23 (6) 20 (6) 65 (6) 0.690 0.661
Mean [days (SD)] 3.3 (4.8) 3.1 (5.0) 2.9 (3.9) 3.1 (4.6)
Median [days (IQR)]b 2.0 (1–4) 2.0 (0–4) 2.0 (0–4) 2.0 (0–4) 0.715 0.630
Days on ward
Number (%) with
any ward staya
247 (74) 275 (70) 258 (72) 780 (72) 0.954 0.169
Mean [days (SD)] 3.3 (4.8) 3.1 (5.0) 2.9 (3.9) 3.1 (4.6)
Median [days (IQR)]b 2.0 (1–4) 2.0 (0–4) 2.0 (0–4) 2.0 (0–4) 0.612 0.323
IQR, interquartile range.
a p-values from chi-squared test.
b p-values from Mann–Whitney U-test.
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TABLE 18 Use of ventilation or respiratory support
Classification
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Required ventilationa 3 (1%) 6 (2%) 4 (1%) 13 (1%)
Non-invasive
ventilationa
2 (1%) 2 (1%) 3 (1%) 7 (1%)
Emergency
intubationa
2 (1%) 4 (1%) 1 (< 1%) 7 (1%)
Comparisons Odds ratio (95% CI) p-value
Active vs. placebo 1.05 (0.31 to 3.51) 0.936
i.v. vs. nebuliser 1.70 (0.42 to 6.83) 0.458
i.v. vs. placebo 1.37 (0.38 to 4.89) 0.629
Nebuliser vs. placebo 0.81 (0.18 to 3.63) 0.780
a Values in brackets denote per cent of total.
One patient had both non-invasive intubation and emergency intubation.
Model for comparison does not include site due to sparse numbers.
RESULTS
38Tables 19–22 show the change in heart rate, respiratory rate and blood pressure (systolic and diastolic)
over the first 2 hours after initiation of treatment. These changes are also shown in Figures 6–9. Mean
values of all four parameters fell during treatment, but there were no significant differences between the
treatment groups in the magnitude of change.TABLE 19 Heart rate (beats per minute) during and after trial treatment
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Pulse at baseline
Number of
observations
331 394 356 1081
Mean [beats
per minute (SD)]
111.1 (19.8) 112.0 (19.1) 110.4 (18.9) 111.2 (19.2)
Median [beats
per minute (IQR)]
112.0 (97–123) 112.0 (98–124) 110.5 (98–123) 112.0 (98–123)
Min., Max. (beats
per minute)
52, 177 60, 168 54, 180 52, 180
Pulse at 1 hour
Number of
observations
326 387 353 1066
Mean [beats
per minute (SD)]
106.8 (18.0) 106.2 (18.6) 106.5 (18.1) 106.5 (18.2)
Median [beats
per minute (IQR)]
107.0 (95–119) 106.0 (94–119) 106.0 (94–119) 106.0 (94–119)
Min., max. (beats
per minute)
61, 162 59, 162 52, 164 52, 164
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TABLE 19 Heart rate (beats per minute) during and after trial treatment (continued )
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Change in pulse at 1 hour
Number of
observations
326 387 353 1066
Mean [beats
per minute (SD)]
–4.4 (13.0) –5.7 (12.7) –3.9 (12.3) –4.7 (12.7)
Median [beats
per minute (IQR)]
–4.0 (–12 to 3) –6.0 (–13 to 1) –2.0 (–10 to 3) –4.0 (–12 to 3)
Min., max. (beats
per minute)
–50, 54 –42, 46 –45, 44 –50, 54
Pulse at 2 hours
Number of
observations
311 379 340 1030
Mean [beats
per minute (SD)]
104.9 (17.3) 105.7 (18.1) 105.9 (17.5) 105.5 (17.7)
Median [beats
per minute (IQR)]
104.0 (93–118) 105.0 (92–117) 105.0 (95–118) 105.0 (93–117)
Min., max. (beats
per minute)
62, 166 57, 164 52, 160 52, 166
Change in pulse at 2 hours
Number of
observations
311 379 340 1030
Mean [beats
per minute (SD)]
–6.3 (15.1) –6.3 (14.7) –4.5 (14.4) –5.7 (14.7)
Median [beats
per minute (IQR)]
–5.0 (–16 to 3) –6.0 (–15 to 2) –4.0 (–14 to 4) –5.0 (–15 to 3)
Min., max. (beats
per minute)
–60, 34 –50, 53 –52, 40 –60, 53
Comparisons Mean difference [beats per minute (95% CI)] p-value
Active vs. placebo –1.8 (–3.7 to 0.1) 0.067
i.v. vs. nebuliser –0.1 (–2.3 to 2.1) 0.940
i.v. vs. placebo –1.8 (–4.0 to 0.3) 0.096
Nebuliser vs. placebo –1.8 (–4.0 to 0.5) 0.130
IQR, interquartile range; max., maximum; min., minimum.
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TABLE 20 Respiratory rate (breaths per minute) during and after trial treatment
Measurement
Nebulised
magnesium
sulphate (n = 332)
Intravenous
magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Respiratory rate at baseline
Number of observations 330 392 356 1078
Mean [breaths
per minute (SD)]
25.7 (7.2) 25.4 (6.4) 25.2 (6.3) 25.4 (6.6)
Median [breaths
per minute (IQR)]
24.0 (20–29) 25.0 (21–28) 24.0 (20–29) 24.0 (20–28)
Min., max. (breaths per minute) 12, 58 10, 48 13, 45 10, 58
Respiratory rate at 1 hour
Number of observations 323 383 350 1056
Mean [breaths
per minute (SD)]
22.7 (6.3) 22.1 (5.9) 21.8 (5.3) 22.2 (5.8)
Median [breaths
per minute (IQR)]
21.0 (19–25) 20.0 (18–24) 20.0 (18–24) 20.0 (18–24)
Min., max. (breaths per minute) 8, 50 11, 48 11, 40 8, 50
Change in respiratory rate at 1 hour
Number of observations 323 381 350 1054
Mean [breaths
per minute (SD)]
−3.1 (5.9) −3.4 (5.6) −3.3 (5.4) −3.3 (5.6)
Median [breaths
per minute (IQR)]
−2.0 (–6 to 0) −3.0 (−6 to 0) −2.0 (−6 to 0) −2.0 (−6 to 0)
Min., max. (breaths per minute) −24, 20 −24, 21 −20, 11 −24, 21
Respiratory rate at 2 hours
Number of observations 307 376 336 1019
Mean [breaths
per minute (SD)]
21.3 (5.7) 20.6 (5.3) 21.0 (5.4) 21.0 (5.5)
Median [breaths
per minute (IQR)]
20.0 (18–24) 20.0 (18–23) 20.0 (18–24) 20.0 (18–24)
Min., max. (breaths per minute) 10, 60 11, 48 9, 48 9, 60
Change in respiratory rate at 2 hours
Number of observations 307 374 336 1017
Mean [breaths
per minute (SD)]
−4.3 (7.0) −4.8 (5.9) −4.2 (6.3) −4.5 (6.4)
Median [breaths
per minute (IQR)]
−4.0 (−8 to 0) −4.0 (−8 to −1) −4.0 (–8 to 0) −4.0 (–8 to 0)
Min., max. (breaths per minute) −38, 16 −30, 12 −27, 14 −38, 16
Comparisons Mean difference [breaths per minute (95% CI)] p-value
Active vs. placebo –0.5 (–1.3 to 0.4) 0.264
i.v. vs. nebuliser –0.4 (–1.4 to 0.5) 0.396
i.v. vs. placebo –0.7 (–1.6 to 0.3) 0.154
Nebuliser vs. placebo –0.3 (–1.3 to 0.7) 0.594
IQR, interquartile range; max., maximum; min., minimum.
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TABLE 21 Systolic blood pressure (mmHg) during and after trial treatment
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Systolic BP at baseline
Number of
observations
330 392 356 1078
Mean [mmHg (SD)] 132.5 (20.4) 133.1 (20.6) 130.6 (19.7) 132.1 (20.2)
Median [mmHg (IQR)] 129.5 (118–142) 130.0 (118–145) 129.0 (116–141) 130.0 (118–143)
Min., max. 84, 230 93, 216 86, 235 84, 235
Systolic BP at 1 hour
Number of
observations
323 383 351 1057
Mean [mmHg (SD)] 128.2 (19.4) 125.2 (15.8) 126.6 (17.2) 126.6 (17.4)
Median [mmHg (IQR)] 125.0 (116–140) 124.0 (115–133) 125.0 (114–137) 124.0 (115–137)
Min., max. (mmHg) 80, 215 79, 186 85, 203 79, 215
Change in systolic BP at 1 hour
Number of
observations
322 381 351 1054
Mean [mmHg (SD)] −4.5 (17.8) −7.8 (19.4) −4.2 (18.1) −5.6 (18.6)
Median [mmHg (IQR)] −4.5 (–14 to 5) −6.0 (–17 to 4) −3.0 (–14 to 6) −4.0 (–15 to 5)
Min., max. (mmHg) −65, 74 −82, 92 −71, 48 −82, 92
Systolic BP at 2 hours
Number of
observations
309 373 338 1020
Mean [mmHg (SD)] 127.0 (19.3) 125.5 (16.5) 124.9 (18.5) 125.7 (18.1)
Median [mmHg (IQR)] 124.0 (114–137) 124.0 (114–134) 122.0 (112–134) 123.0 (114–135)
Min., max. (mmHg) 85, 194 88, 187 76, 212 76, 212
Change in systolic BP at 2 hours
Number of
observations
309 371 338 1018
Mean [mmHg (SD)] −5.6 (19.9) −7.7 (18.2) −6.1 (19.5) –6.5 (19.2)
Median [mmHg (IQR)] −5.0 (–17 to 6) −7.0 (–16 to 4) −5.0 (–17 to 6) −5.5 (–17 to 5)
Min., max. (mmHg) −82, 51 −82, 60 −78, 47 −82, 60
Comparisons Mean difference [mmHg (95% CI)] p-value
Active vs. placebo –0.6 (–3.1 to 2.0) 0.664
i.v. vs. nebuliser –1.8 (–4.7 to 1.1) 0.214
i.v. vs. placebo –1.5 (–4.3 to 1.4) 0.308
Nebuliser vs. placebo 0.4 (–2.6 to 3.3) 0.810
BP, blood pressure; IQR, interquartile range; max., maximum; min., minimum.
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TABLE 22 Diastolic blood pressure (mmHg) during and after trial treatment
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Diastolic BP at baseline
Number of
observations
330 391 356 1077
Mean [mmHg (SD)] 76.3 (15.5) 75.7 (14.8) 75.0 (15.1) 75.6 (15.1)
Median [mmHg (IQR)] 75.0 (66–86) 74.0 (66–85) 74.0 (65–84) 74.0 (65–85)
Min., max. (mmHg) 30, 151 38, 135 33, 145 30, 151
Diastolic BP at 1 hour
Number of
observations
323 383 351 1057
Mean [mmHg (SD)] 73.2 (14.4) 69.3 (11.5) 70.8 (13.5) 71.0 (13.2)
Median [mmHg (IQR)] 73.0 (64–81) 69.0 (61–77) 70.0 (62–79) 71.0 (62–78)
Min., max. (mmHg) 36, 135 30, 115 32, 133 30, 135
Change in diastolic BP at 1 hour
Number of
observations
322 380 351 1053
Mean [mmHg (SD)] –3.4 (14.1) –6.3 (13.8) –4.2 (13.6) –4.7 (13.9)
Median [mmHg (IQR)] –2.0 (–11 to 5) –5.0 (–13 to 2) –4.0 (–12 to 3) –4.0 (–12 to 3)
Min., max. (mmHg) –65, 49 –67, 41 –72, 69 –72, 69
Diastolic BP at 2 hours
Number of
observations
309 372 337 1018
Mean [mmHg (SD)] 70.6 (13.9) 68.3 (12.3) 69.7 (14.3) 69.4 (13.5)
Median [mmHg (IQR)] 69.0 (62–80) 68.0 (61–76) 69.0 (61–78) 69.0 (61–78)
Min., max. (mmHg) 35, 117 32, 113 37, 148 32, 148
Change in diastolic BP at 2 hours
Number of
observations
309 369 337 1015
Mean [mmHg (SD)] –5.8 (14.4) –7.5 (14.9) –5.4 (14.6) –6.3 (14.7)
Median [mmHg (IQR)] –5.0 (–15 to 4) –7.0 (–16 to 2) –5.0 (–14 to 4) –6.0 (–15 to 3)
Min., max. (mmHg) –53, 31 –81, 40 –72, 35 –81, 40
Comparisons Mean difference [mmHg (95% CI)] p-value
Active vs. placebo –1.1 (–3.0 to 0.8) 0.248
i.v. vs. nebuliser –1.6 (–3.8 to 0.6) 0.151
i.v. vs. placebo –1.9 (–4.1 to 0.2) 0.080
Nebuliser vs. placebo –0.3 (–2.6 to 1.9) 0.782
BP, blood pressure; IQR, interquartile range; max., maximum; min., minimum.
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FIGURE 6 Heart rate (beats per minute) during and after trial treatment. Neb, nebuliser; Pla, placebo.
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FIGURE 7 Respiratory rate (breaths per minute) during and after trial treatment. Neb, nebuliser; Pla, placebo.
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FIGURE 8 Systolic blood pressure (mmHg) during and after trial treatment. Neb, nebuliser; Pla, placebo.
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FIGURE 9 Diastolic blood pressure (mmHg) during and after trial treatment. Neb, nebuliser; Pla, placebo.
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44Table 23 shows the change in peripheral oxygen saturation over the first 2 hours after initiation of
treatment. Three-quarters of the cohort were receiving supplemental oxygen at baseline. The proportion
of participants receiving supplemental oxygen increased at 1 hour and then decreased at 2 hours. This
means that the analysis of peripheral oxygen saturation, shown separately for those receiving and not
receiving supplemental oxygen, includes different patients at different times. Unsurprisingly, there is little
change in the peripheral oxygen saturation over time and little difference between groups, since
administration of oxygen is likely to be titrated in response to demand and/or peripheral oxygen saturation.
Patients receiving supplemental oxygen had a mean peripheral oxygen saturation of around 98%, whereas
those patients not receiving supplemental oxygen had a peripheral oxygen saturation of 96–97%.
If the trial treatment had influenced oxygenation then this might have been apparent in terms of reduced
requirement for inspired oxygen. Table 24 and Figure 10 show the change in inspired oxygen flow rate
over the first 2 hours after initiation of treatment. Patients not receiving oxygen were analysed as having a
flow rate of 0 l/minute. Patients allocated to i.v. magnesium sulphate had a slightly lower oxygen flow rate
at 2 hours than patients allocated to nebulised magnesium sulphate, but there were no significant
differences between either treatment arm and placebo.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 23 Peripheral oxygen saturation during and after trial treatment
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Mode of delivery at baselinea
On oxygen 256 (77%) 294 (75%) 259 (72%) 809 (75%)
On air 75 (23%) 99 (25%) 95 (27%) 269 (25%)
Not recorded 1 (< 1%) 1 (< 1%) 4 (1%) 6 (1%)
Mode of delivery at 1 houra
On oxygen 285 (86%) 338 (86%) 299 (84%) 922 (85%)
On air 39 (12%) 45 (11%) 51 (14%) 135 (12%)
Not recorded 8 (2%) 11 (3%) 8 (2%) 27 (2%)
Mode of delivery at 2 hoursa
On oxygen 213 (64%) 224 (57%) 199 (56%) 636 (59%)
On air 99 (30%) 154 (39%) 138 (39%) 391 (36%)
Not recorded 20 (6%) 16 (4%) 21 (6%) 57 (5%)
Patients on oxygen
Oxygen saturation at baseline (%)
Number of
observations
256 294 259 809
Mean [% (SD)] 97.8 (2.1) 97.9 (2.3) 98.0 (2.2) 97.9 (2.2)
Median [% (IQR)] 98.0 (97–100) 98.5 (97–100) 99.0 (97–100) 98.0 (97–100)
Min., max. (%) 91, 100 88, 100 90, 100 88, 100
Oxygen saturation at 1 hour (%)
Number of
observations
285 338 299 922
Mean [% (SD)] 98.2 (1.9) 98.3 (1.9) 98.3 (1.9) 98.2 (1.9)
Median [% (IQR)] 99.0 (97–100) 99.0 (97–100) 99.0 (97–100) 99.0 (97–100)
Min., max. (%) 91, 100 89, 100 90, 100 89, 100
Change in oxygen saturation at 1 hour (%)
Number of
observations
235 266 234 735
Mean [% (SD)] 0.3 (2.0) 0.3 (2.0) 0.3 (1.9) 0.3 (2.0)
Median [% (IQR)] 0.0 (–1 to 1) 0.0 (–1 to 1) 0.0 (–1 to 1) 0.0 (–1 to 1)
Min., max. (%) –5, 6 –5, 9 –5, 7 –5, 9
Oxygen saturation at 2 hours (%)
Number of
observations
213 224 199 636
Mean [% (SD)] 97.7 (2.3) 97.7 (2.1) 97.8 (2.2) 97.7 (2.2)
Median [% (IQR)] 98.0 (96–100) 98.0 (97–99) 98.0 (96–100) 98.0 (96–100)
Min., max. (%) 90, 100 90, 100 90, 100 90, 100
continued
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TABLE 23 Peripheral oxygen saturation during and after trial treatment (continued )
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Change in oxygen saturation at 2 hours (%)
Number of
observations
176 181 164 521
Mean [% (SD)] –0.0 (2.3) –0.1 (2.3) –0.2 (2.1) –0.1 (2.2)
Median [% (IQR)] 0.0 (–1 to 1) 0.0 (–1 to 1) 0.0 (–1 to 1) 0.0 (–1 to 1)
Min., max. (%) –6, 6 –8, 7 –7, 7 –8, 7
Patients on air
Oxygen saturation at baseline (%)
Number of
observations
75 99 95 269
Mean [% (SD)] 96.3 (2.6) 95.9 (2.5) 95.9 (2.6) 96.0 (2.6)
Median [% (IQR)] 96.0 (95–98) 96.0 (94–98) 96.0 (94–98) 96.0 (94–98)
Min., max. (%) 88, 100 87, 100 85, 100 85, 100
Oxygen saturation at 1 hour (%)
Number of
observations
39 45 51 135
Mean [% (SD)] 96.6 (2.6) 96.6 (2.9) 97.1 (2.4) 96.8 (2.7)
Median [% (IQR)] 98.0 (95–98) 97.0 (95–99) 98.0 (95–99) 98.0 (95–99)
Min., max. (%) 92, 100 88, 100 92, 100 88, 100
Change in oxygen saturation at 1 hour (%)
Number of
observations
24 25 30 79
Mean [% (SD)] 0.0 (2.0) 1.0 (2.1) 1.5 (2.6) 0.9 (2.3)
Median [% (IQR)] 0.0 (–2 to 2) 1.0 (0 to 3) 1.0 (–1 to 4) 1.0 (–1 to 3)
Min., max. (%) –6, 3 –4, 4 –2, 7 –6, 7
Oxygen saturation at 2 hours (%)
Number of
observations
99 154 138 391
Mean [% (SD)] 96.4 (2.6) 96.3 (2.7) 96.4 (2.4) 96.4 (2.6)
Median [% (IQR)] 96.0 (95–99) 97.0 (95–98) 96.0 (95–98) 96.0 (95–98)
Min., max. (%) 87, 100 86, 100 85, 100 85, 100
Change in oxygen saturation at 2 hours (%)
Number of
observations
34 52 56 142
Mean [% (SD)] –0.0 (2.6) –0.1 (2.4) 0.5 (2.6) 0.2 (2.5)
Median [% (IQR)] 0.0 (–1 to 1) 0.0 (–1 to 1) 0.0 (–1 to 2) 0.0 (–1 to 1)
Min., max. (%) –7, 6 –9, 4 –4, 10 –9, 10
IQR, interquartile range; max., maximum; min., minimum.
a Values in brackets denote per cent of total.
RESULTS
46
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 24 Inspired oxygen flow rate (l/minute) during and after trial treatment
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Oxygen flow at baseline
Number of
observations
324 387 344 1055
Mean [l/minute (SD)] 5.1 (3.5) 5.3 (4.0) 4.8 (3.6) 5.1 (3.7)
Median [l/minute (IQR)] 6.0 (2–6) 6.0 (0–6) 6.0 (0–6) 6.0 (0–6)
Min., max. (l/minute) 0, 15 0, 15 0, 15 0, 15
Oxygen flow at 1 hour
Number of
observations
315 377 339 1031
Mean [l/minute (SD)] 5.6 (2.6) 5.6 (2.6) 5.3 (2.7) 5.5 (2.6)
Median [l/minute (IQR)] 6.0 (5–6) 6.0 (6–6) 6.0 (5–6) 6.0 (5–6)
Min., max. (l/minute) 0, 15 0, 15 0, 15 0, 15
Change in oxygen flow at 1 hour
Number of
observations
312 372 331 1015
Mean [l/minute (SD)] 0.5 (3.4) 0.4 (3.9) 0.5 (3.7) 0.5 (3.7)
Median [l/minute (IQR)] 0.0 (0–1) 0.0 (0–2) 0.0 (0–2) 0.0 (0–2)
Min., max. (l/minute) –10, 10 –11, 10 –15, 10 –15, 10
Oxygen flow at 2 hours (l/minute)
Number of
observations
301 364 326 991
Mean [l/minute (SD)] 4.4 (3.7) 3.6 (3.5) 3.6 (3.5) 3.8 (3.5)
Median [l/minute (IQR)] 6.0 (0–6) 5.0 (0–6) 5.0 (0–6) 5.0 (0–6)
Min., max. (l/minute) 0, 15 0, 15 0, 15 0, 15
Change in oxygen flow at 2 hours (l/minute)
Number of
observations
299 361 320 980
Mean [l/minute (SD)] –0.7 (4.3) –1.6 (4.8) –1.3 (4.2) –1.2 (4.5)
Median [l/minute (IQR)] 0.0 (–4 to 0) 0.0 (–6 to 0) 0.0 (–5 to 0) 0.0 (–5 to 0)
Min., max. (l/minute) –15, 10 –15, 10 –15, 10 –15, 10
Comparisons Mean difference [l/minute (95% CI)] p-value
Active vs. placebo 0.0 (–0.6 to 0.6) 0.942
i.v. vs. nebuliser –0.9 (–1.6 to –0.2) 0.008
i.v. vs. placebo –0.4 (–1.1 to 0.2) 0.196
Nebuliser vs. placebo 0.5 (–0.2 to 1.2) 0.173
IQR, interquartile range; max., maximum; min., minimum.
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FIGURE 10 Oxygen flow rate (l/minute) during and after trial treatment. Neb, nebuliser; Pla, placebo.
RESULTS
48Table 25 and Figure 11 show the change in PEFR over the first 2 hours after initiation of treatment, and
Table 26 and Figure 12 show these data as percentage of predicted PEFR. Mean PEFR and percentage
predicted PEFR improved markedly in all three treatment groups over the 2 hours. The IQR for percentage
predicted PEFR at 2 hours indicates that after treatment only around one-quarter of the cohort were
recording a PEFR < 50% of predicted. Comparison of the three groups shows no evidence of any effect
from i.v. or nebulised magnesium sulphate on PEFR.Adverse events and side effectsTable 27 shows the adverse events recorded up to 30 days and Table 28 shows those adverse events
which were classified as being SAEs. There were very few adverse events in the prespecified categories:
seven patients required intubation, seven patients required non-invasive ventilation, two patients suffered
an arrhythmia, one patient suffered a cardiac arrest and two patients died. However, the definition of an
adverse event used in the trial included any subsequent hospitalisation. A substantial number of patients
were therefore recorded as having an adverse event by virtue of subsequent admission to hospital, either
due to worsening of their asthma or other unrelated problems.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 25 Peak expiratory flow rate (l/minute) during and after trial treatment
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
PEFR at baseline
Number of
observations
312 379 336 1027
Mean [l/minute (SD)] 209.1 (92.3) 226.8 (92.3) 214.5 (84.0) 217.4 (89.9)
Median [l/minute (IQR)] 200.0 (150–250) 210.0 (150–270) 200.0 (150–255) 200.0 (150–260)
Min., max. (l/minute) 50, 620 50, 530 50, 520 50, 620
PEFR at 1 hour
Number of
observations
293 358 324 975
Mean [l/minute (SD)] 255.2 (109.8) 275.6 (104.9) 259.0 (100.2) 263.9 (105.2)
Median [l/minute (IQR)] 240.0 (170–330) 260.0 (190–350) 250.0 (180–330) 250.0 (180–340)
Min., max. (l/minute) 50, 590 50, 650 60, 700 50, 700
Change in PEFR at 1 hour
Number of
observations
284 351 312 947
Mean [l/minute (SD)] 43.3 (63.9) 48.2 (66.0) 45.3 (65.1) 45.8 (65.0)
Median [l/minute (IQR)] 30.0 (0–70) 30.0 (0–90) 30.0 (3–70) 30.0 (0–70)
Min., max. (l/minute) –110, 330 –100, 350 –60, 580 –110, 580
PEFR at 2 hours
Number of
observations
281 348 310 939
Mean [l/minute (SD)] 270.4 (117.4) 288.1 (111.2) 278.9 (105.5) 279.8 (111.4)
Median [l/minute (IQR)] 250.0 (190–350) 280.0 (200–355) 270.0 (200–350) 270.0 (200–350)
Min., max. (l/minute) 50, 800 50, 650 50, 600 50, 800
Change in PEFR at 2 hours
Number of
observations
272 339 298 909
Mean [l/minute (SD)] 58.3 (77.3) 61.0 (73.6) 62.5 (69.4) 60.7 (73.3)
Median [l/minute (IQR)] 40.0 (5–95) 40.0 (10–90) 50.0 (20–100) 40.0 (10–100)
Min., max. (l/minute) –89, 500 140, 410 80, 390 –140, 500
Comparisons Mean difference [l/minute (95% CI)] p-value
Active vs. placebo –2.5 (–12.5 to 7.5) 0.625
i.v. vs. nebuliser 0.3 (–11.2 to 11.7) 0.964
i.v. vs. placebo –2.4 (–13.6 to 8.8) 0.680
Nebuliser vs. placebo –2.6 (–14.5 to 9.2) 0.664
IQR, interquartile range; max., maximum; min., minimum.
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FIGURE 11 Peak expiratory flow rate (l/minute) during and after trial treatment. Neb, nebuliser; Pla, placebo.
TABLE 26 Peak expiratory flow rate (% of predicted) during and after trial treatment
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
% PEFR at baseline
Number of
observations
308 375 327 1010
Mean [% of
predicted (SD)]
50.0 (19.6) 54.3 (20.2) 50.5 (19.1) 51.7 (19.7)
Median [% of
predicted (IQR)]
47.5 (35–61) 50.0 (40–67) 48.0 (37–63) 50.0 (38–63)
Min., max. (% of
predicted)
11, 116 12, 160 9, 112 9, 160
% PEFR at 1 hour
Number of
observations
290 356 315 961
Mean [% of
predicted (SD)]
60.3 (22.8) 65.5 (22.7) 60.1 (20.9) 62.1 (22.3)
Median [% of
predicted (IQR)]
57.1 (43–77) 63.0 (50–80) 60.0 (44–73) 60.0 (45–78)
Min., max. (% of
predicted)
17, 125 13, 140 13, 125 13, 140
% change in PEFR at 1 hour
Number of
observations
282 349 304 935
Mean [% of
predicted (SD)]
9.9 (15.0) 11.4 (15.7) 10.2 (14.7) 10.6 (15.2)
Median [% of
predicted (IQR)]
7.0 (0–17) 6.8 (0–20) 7.5 (0–16) 7.0 (0–17)
Min., max. (% of
predicted)
–40, 63 –24, 75 –27, 97 –40, 97
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TABLE 26 Peak expiratory flow rate (% of predicted) during and after trial treatment (continued )
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
% PEFR at 2 hours
Number of
observations
278 346 301 925
Mean [% of
predicted (SD)]
63.1 (24.0) 68.6 (23.3) 65.0 (22.7) 65.8 (23.5)
Median [% of
predicted (IQR)]
60.0 (46–78) 68.3 (52–86) 64.9 (47–80) 64.0 (49–81)
Min., max. (% of
predicted)
16, 160 13, 144 10, 164 10, 164
% change in PEFR at 2 hours
Number of
observations
270 337 291 898
Mean [% of predicted
(SD)]
13.4 (18.0) 14.4 (17.4) 14.4 (16.3) 14.1 (17.2)
Median [% of
predicted (IQR)]
9.8 (1–22) 10.9 (3–23) 10.9 (4–22) 10.4 (3–22)
Min., max. (% of
predicted)
–36, 100 –30, 83 –18, 103 –36, 103
Comparisons Mean difference [% of predicted (95% CI)] p-value
Active vs. placebo –0.5 (–2.9 to 1.9) 0.676
i.v. vs. nebuliser 0.3 (–2.4 to 3.0) 0.841
i.v. vs. placebo –0.4 (–3.0 to 2.3) 0.786
Nebuliser vs. placebo –0.6 (–3.4 to 2.1) 0.652
IQR, interquartile range; max., maximum; min., minimum.
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FIGURE 12 Peak expiratory flow rate (% of predicted) during and after trial treatment. Neb, nebuliser; Pla, placebo.
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TABLE 27 Adverse events up to 30 days
Adverse event
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 395)
Placebo
(n = 358)
Overall
(n = 1085)
Any adverse event 41 (12.3%) 53 (13.4%) 36 (10.1%) 130 (12.0%)
Arrhythmia 0 1 (0.3%) 1 (0.3%) 2 (0.2%)
Cardiac arrest 0 1 (0.3%) 0 1 (0.1%)
Death 1 (0.3%) 1 (0.3%) 0 2 (0.2%)
Intubation 2 (0.6%) 4 (1.0%) 1 (0.3%) 7 (0.6%)
Non-invasive
ventilation
2 (0.6%) 2 (0.5%) 3 (0.8%) 7 (0.6%)
Other asthma
related
26 (7.8%) 25 (6.3%) 22 (6.1%) 73 (6.7%)
Other non-asthma
related
14 (4.2%) 20 (5.1%) 12 (3.4%) 46 (4.2%)
Numbers refer to patients experiencing an event of each type.
Values in brackets denote per cent of total.
Total number of events will not equal the sum of events per individual if a patient experiences multiple events.
TABLE 28 Serious adverse events up to 30 days
Adverse event
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 395)
Placebo
(n = 358)
Overall
(n = 1085)
Any serious
adverse event
35 (10.5%) 45 (11.4%) 28 (7.8%) 108 (10.0%)
Arrhythmia 0 1 (0.3%) 0 1 (0.1%)
Cardiac arrest 0 1 (0.3%) 0 1 (0.1%)
Death 1 (0.3%) 1 (0.3%) 0 2 (0.2%)
Intubation 2 (0.6%) 4 (1.0%) 1 (0.3%) 7 (0.6%)
Non-invasive
ventilation
0 1 (0.3%) 3 (0.8%) 4 (0.4%)
Other asthma
related
24 (7.2%) 23 (5.8%) 21 (5.9%) 68 (6.3%)
Other non-asthma
related
8 (2.4%) 14 (3.6%) 5 (1.4%) 27 (2.5%)
Numbers refer to patients experiencing an event of each type.
Values in brackets denote per cent of total.
Total number of events will not equal the sum of events per individual if a patient experiences multiple events.
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DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22Table 29 shows the potential side effects recorded during or after trial treatment. The rate of side
effects that have previously been reported in association with administration of magnesium sulphate
(flushing, hypotension, nausea and vomiting) were generally low and were only slightly higher in the
active treatment arms than the placebo arm. Overall, side effects were a little more common in
the active treatment arms than the placebo arm [15.6% vs. 10.1%, odds ratio (OR) 1.68 (95% CI 1.11
to 2.52; p = 0.014)].Thirty-day outcomesOverall, 504 (47%) of the 30-day outcome questionnaires were returned. Table 30 shows the 30-day
questionnaire response rate by age group and sex. Females were more likely to respond than males and
the percentage response increased with participant age.
Figure 13 shows the overall distribution of EQ-5D scores and Table 31 shows patient-reported health
utility, at baseline and 30 days, measured on the EQ-5D survey. The placebo group had a slightly higherTABLE 29 Side effects recorded during or after trial treatment
Side effect
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1085)
Any side effecta 52 (15.7%) 61 (15.5%) 36 (10.1%) 149 (13.7%)
Flushinga 3 (0.9%) 7 (1.8%) 2 (0.6%) 12 (1.1%)
Hypotensiona 31 (9.3%) 31 (7.8%) 22 (6.1%) 84 (7.7%)
Nauseaa 5 (1.5%) 14 (3.5%) 7 (2.0%) 26 (2.4%)
Vomitinga 6 (1.8%) 6 (1.5%) 3 (0.8%) 15 (1.4%)
Othera 12 (3.6%) 15 (3.8%) 5 (1.4%) 32 (2.9%)
Comparisonsb Odds ratio (95% CI) p-value
Active vs. placebo 1.68 (1.11 to 2.52) 0.014
i.v. vs. nebuliser 1.00 (0.66 to 1.52) 0.988
i.v. vs. placebo 1.68 (1.07 to 2.63) 0.025
Nebuliser vs.
placebo
1.67 (1.05 to 2.66) 0.031
a Value in brackets denotes per cent of total.
b Comparison is any side effect (yes/no).
Numbers refer to patients experiencing a side effect of each type.
The total number of events will not equal the sum of side effects per individual if a patient experiences multiple side effects.
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TABLE 30 Response rate according to sex and age group
Age group (years)
n (%) response
Males Females
< 25 22 (28) 87 (43)
25–34 23 (30) 91 (47)
35–44 25 (35) 79 (49)
45–54 35 (59) 73 (55)
55–64 11 (55) 34 (62)
65–74 6 (55) 12 (86)
≥ 75 3 (60) 3 (60)
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FIGURE 13 Distribution of EQ-5D scores. EQ-5D values at 30 days.
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TABLE 31 Patient-reported health utility (EQ-5D)
Measurement
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Baseline
Number (%) of
responses
282 (84.9) 341 (86.5) 309 (86.3) 932 (86.0)
Mean (SD) 0.734 (0.327) 0.726 (0.354) 0.746 (0.323) 0.735 (0.336)
Median (IQR) 0.814 (0.69–1.00) 0.814 (0.69–1.00) 0.883 (0.69–1.00) 0.848 (0.64–1.00)
Min., max. –0.35, 1.00 –0.59, 1.00 –0.35, 1.00 –0.59, 1.00
One month
Number (%) of
responses
160 (48.2) 169 (42.9) 173 (48.3) 502 (46.3)
Mean (SD) 0.721 (0.326) 0.731 (0.329) 0.810 (0.250) 0.755 (0.305)
Median (IQR) 0.814 (0.62–1.00) 0.814 (0.62–1.00) 0.883 (0.69–1.00) 0.848 (0.64–1.00)
Min., max. –0.35, 1.00 –0.32, 1.00 –0.08, 1.00 –0.35, 1.00
Change in EQ-5D score at 1 month
Number (%) of
responses
140 (42.2) 146 (37.1) 151 (42.2) 437 (40.3)
Mean (SD) 0.037 (0.377) 0.035 (0.357) 0.041 (0.341) 0.038 (0.358)
Median (IQR) 0.00 (–0.10 to 0.20) 0.00 (–0.15 to 0.19) 0.00 (–0.12 to 0.15) 0.00 (–0.11 to 0.19)
Min., max. –1.07, 1.09 –1.02, 1.48 –1.02, 1.32 –1.07, 1.48
Comparisons Difference (95% CI) p-value
Active vs. placebo –0.01 (–0.08 to 0.06) 0.842
i.v. vs. nebuliser –0.00 (–0.09 to 0.08) 0.961
i.v. vs. placebo –0.01 (–0.09 to 0.07) 0.884
Nebuliser vs.
placebo
–0.01 (–0.09 to 0.08) 0.844
Comparison of baseline scores (responders vs. non-responders)
Difference –0.10 –0.05 0.03 –0.04
(95% CI) –0.17 to –0.02 –0.13 to 0.02 –0.04 to 0.10 –0.08 to 0.01
p-value 0.014 0.179 0.456 0.085
IQR, interquartile range; max., maximum; min., minimum.
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56baseline mean score than the nebulised group, which was in turn higher than the i.v. group. There were
only small changes in EQ-5D score from baseline to 30 days and no significant differences between the
groups. Health utility data for the normal UK population were used to calculate a regional age- and
sex-adjusted expected normal value for each patient.68 The results are shown in Figure 14. At 30 days, the
responders had a significantly lower EQ-5D than age- or sex-matched UK norms (mean loss = –0.14,
95% CI –0.17 to –0.11; p < 0.001).
The 30-day questionnaire also asked patients to describe which NHS resources they had used in the
30 days following randomisation and these are described in Table 32. No obvious differences were noted
between the groups, but most patients (74%) had at least one GP contact and reattendances at hospital
were common, either as an outpatient (36%) or as an admission (29%).Nebulised
magnesium sulphate
i.v.
magnesium sulphate
Treatment group
Placebo
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FIGURE 14 EQ-5D score loss at 30 days compared with age- or sex-matched UK norms.
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TABLE 32 Use of health and social services over the following month
Health or social service
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Number (%) of responders 138 (42%) 151 (38%) 144 (40%) 433 (40%)
Use of telephone health advice
None 97 (70%) 103 (68%) 107 (74%) 307 (71%)
1 19 (14%) 22 (15%) 17 (12%) 58 (13%)
2 6 (4%) 8 (5%) 11 (8%) 25 (6%)
3 or more 16 (12%) 18 (12%) 9 (6%) 43 (10%)
Use of GP surgery consultations
None 39 (28%) 43 (28%) 39 (27%) 121 (28%)
1 37 (27%) 33 (22%) 31 (22%) 101 (23%)
2 24 (17%) 28 (19%) 35 (24%) 87 (20%)
3 16 (12%) 17 (11%) 18 (13%) 51 (12%)
4 or more 22 (16%) 30 (20%) 21 (15%) 73 (17%)
GP home visits
None 131 (95%) 141 (93%) 140 (97%) 412 (95%)
1 or more 7 (5%) 10 (7%) 4 (3%) 21 (5%)
Nurse home visits
None 131 (95%) 145 (96%) 141 (98%) 417 (96%)
1 or more 7 (5%) 6 (4%) 3 (2%) 16 (4%)
Social worker visits
None 130 (94%) 145 (96%) 143 (99%) 418 (97%)
1 or more 8 (6%) 6 (4%) 1 (1%) 15 (3%)
Outpatient attendances
None 83 (60%) 90 (60%) 103 (72%) 276 (64%)
1 35 (25%) 38 (25%) 28 (19%) 101 (23%)
2 14 (10%) 15 (10%) 6 (4%) 35 (8%)
3 or more 6 (4%) 8 (5%) 7 (5%) 21 (5%)
Inpatient nights
None 89 (64%) 106 (70%) 113 (78%) 308 (71%)
1 8 (6%) 5 (3%) 3 (2%) 16 (4%)
2 8 (6%) 5 (3%) 5 (3%) 18 (4%)
3 or more 33 (24%) 35 (23%) 23 (16%) 91 (21%)
Any self-reported medication use
Yes 131 (96%) 144 (97%) 138 (97%) 413 (96%)
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RESULTS
58Table 33 describes the time taken off work in the month following randomisation. Despite the groups
being well matched in respect to age and sex, both at baseline and among responders, the placebo group
contained a lower percentage of patients not in paid employment (31%) than the active groups (i.v. 43%;
nebulised 45%). Restricting the analysis just to those in paid employment, 47% of responders in the
placebo group took time off, compared with 55% in the i.v. magnesium sulphate group and 62% in the
nebulised magnesium sulphate group, although this comparison was not statistically significant
(comparison of active vs. placebo: χ2 = 3.1, p = 0.08). Likewise, the number of days taken off was not
significantly different between groups (Mann–Whitney U-test, p = 0.21). Among patients who had taken
time off work, typically this entailed more than 1 week (median 9 days).
Table 34 shows the results of the 11 questions in the satisfaction with care questionnaire. In general,
satisfaction with care was high across all three treatment groups and across most dimensions of care, with
over 70% rating care as very good or excellent on 8 of the 11 dimensions. The dimensions of care relating
to personal interest in the patient and their medical problems, the amount of time given by hospital staff
and especially advice given about ways to avoid illness and stay healthy were generally rated lower. There
were no significant differences in any of the primary contrasts between the treatment groups.
Table 35 shows the results of questions asking the participants to guess whether they received active
treatment or placebo. Most patients in the active treatment arms (61% of patients in the nebulised group
and 60% of patients in the i.v. group) believed they had received active treatment, compared with 45% of
patients in the placebo group. When asked how they thought they had received magnesium sulphate,
39% of patients in the nebuliser group and 26% of patients in the i.v. group correctly identified the route
of administration. These findings suggest that participants had some ability to correctly identify whether
or not they had received active treatment, but their guessing was only moderately better than that
expected due to chance.TABLE 33 Time taken off work over the following month
Classification
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Number (%) of
responders
138 (42%) 151 (38%) 144 (40%) 433 (40%)
Any time taken off work
Yes 47 (34%) 45 (31%) 46 (32%) 138 (33%)
No 29 (21%) 37 (26%) 52 (37%) 118 (28%)
Not in paid
employment
61 (45%) 63 (43%) 44 (31%) 168 (40%)
Number of days if yes:
≤ 1 day 3 (8%) 0 4 (9%) 7 (6%)
2–3 days 4 (10%) 9 (22%) 7 (15%) 20 (16%)
4–5 days 3 (8%) 5 (12%) 7 (15%) 15 (12%)
6–10 days 6 (15%) 5 (12%) 9 (20%) 20 (16%)
11–15 days 11 (28%) 6 (15%) 6 (13%) 23 (18%)
≥ 16 days 12 (31%) 16 (39%) 13 (28%) 41 (33%)
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TABLE 34 Patient satisfaction with care
Classification
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Number (%) of
questionnaires returned
138 (42%) 151 (38%) 145 (41%) 434 (40%)
The urgency with which you were assessed
Poor 1 (1%) 4 (3%) 1 (1%) 6 (1%)
Fair 8 (6%) 5 (3%) 10 (7%) 23 (5%)
Good 22 (16%) 19 (13%) 25 (17%) 66 (15%)
Very good 42 (30%) 52 (34%) 42 (29%) 136 (31%)
Excellent 65 (47%) 71 (47%) 67 (46%) 203 (47%)
Comparisons p-value
Active vs. placebo 0.592
i.v. vs. nebuliser 0.781
The thoroughness of your assessment
Poor 1 (1%) 1 (1%) 0 2 (< 1%)
Fair 4 (3%) 7 (5%) 9 (6%) 20 (5%)
Good 24 (17%) 20 (13%) 25 (17%) 69 (16%)
Very good 52 (38%) 51 (34%) 51 (35%) 154 (36%)
Excellent 57 (41%) 71 (47%) 60 (41%) 188 (43%)
Comparisons p-value
Active vs. placebo 0.400
i.v. vs. nebuliser 0.368
Explanations given to you about medical procedures and tests
Poor 2 (1%) 5 (3%) 4 (3%) 11 (3%)
Fair 6 (4%) 8 (5%) 9 (6%) 23 (5%)
Good 23 (17%) 15 (10%) 23 (16%) 61 (14%)
Very good 58 (42%) 55 (36%) 46 (32%) 159 (37%)
Excellent 49 (36%) 68 (45%) 63 (43%) 180 (41%)
Comparisons p-value
Active vs. placebo 0.960
i.v. vs. nebuliser 0.157
Attention given to what you have to say
Poor 1 (1%) 6 (4%) 3 (2%) 10 (2%)
Fair 12 (9%) 9 (6%) 15 (10%) 36 (8%)
Good 26 (19%) 26 (17%) 27 (19%) 79 (18%)
Very good 45 (33%) 58 (38%) 53 (37%) 156 (36%)
Excellent 53 (39%) 52 (34%) 47 (32%) 152 (35%)
continued
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TABLE 34 Patient satisfaction with care (continued )
Classification
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Comparisons p-value
Active vs. placebo 0.342
i.v. vs. nebuliser 0.666
Advice you got about ways to avoid illness and stay healthy
Poor 13 (10%) 14 (9%) 9 (6%) 36 (8%)
Fair 28 (21%) 23 (15%) 19 (13%) 70 (16%)
Good 38 (28%) 36 (24%) 39 (27%) 113 (26%)
Very good 30 (22%) 38 (25%) 39 (27%) 107 (25%)
Excellent 26 (19%) 39 (26%) 36 (25%) 101 (24%)
Comparisons p-value
Active vs. placebo 0.143
i.v. vs. nebuliser 0.112
Friendliness and courtesy shown to you by hospital staff
Poor 2 (1%) 1 (1%) 0 3 (1%)
Fair 7 (5%) 7 (5%) 4 (3%) 18 (4%)
Good 21 (15%) 25 (17%) 26 (18%) 72 (17%)
Very good 41 (30%) 43 (28%) 38 (26%) 122 (28%)
Excellent 66 (48%) 75 (50%) 77 (53%) 218 (50%)
Comparisons p-value
Active vs. placebo 0.407
i.v. vs. nebuliser 0.812
Personal interest in you and your medical problems
Poor 1 (1%) 4 (3%) 4 (3%) 9 (2%)
Fair 12 (9%) 19 (13%) 11 (8%) 42 (10%)
Good 35 (25%) 28 (19%) 32 (22%) 95 (22%)
Very good 43 (31%) 49 (33%) 51 (35%) 143 (33%)
Excellent 47 (34%) 50 (33%) 47 (32%) 144 (33%)
Comparisons p-value
Active vs. placebo 0.887
i.v. vs. nebuliser 0.733
Respect shown to you and attention to your privacy
Poor 3 (2%) 2 (1%) 0 5 (1%)
Fair 10 (7%) 8 (5%) 8 (6%) 26 (6%)
Good 28 (20%) 30 (20%) 32 (22%) 90 (21%)
Very good 45 (33%) 47 (31%) 41 (28%) 133 (31%)
Excellent 52 (38%) 64 (42%) 64 (44%) 180 (41%)
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TABLE 34 Patient satisfaction with care (continued )
Classification
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Overall
(n = 1084)
Comparisons p-value
Active vs. placebo 0.484
i.v. vs. nebuliser 0.363
Reassurance and support offered to you by hospital staff
Poor 5 (4%) 7 (5%) 4 (3%) 16 (4%)
Fair 14 (10%) 13 (9%) 13 (9%) 40 (9%)
Good 28 (20%) 23 (15%) 25 (17%) 76 (18%)
Very good 39 (28%) 57 (38%) 45 (31%) 141 (33%)
Excellent 51 (37%) 51 (34%) 58 (40%) 160 (37%)
Comparisons p-value
Active vs. placebo 0.373
i.v. vs. nebuliser 0.922
Amount of time the hospital staff gave you
Poor 4 (3%) 4 (3%) 3 (2%) 11 (3%)
Fair 20 (14%) 22 (15%) 15 (10%) 57 (13%)
Good 30 (22%) 35 (23%) 37 (26%) 102 (24%)
Very good 42 (30%) 47 (31%) 46 (32%) 135 (31%)
Excellent 42 (30%) 43 (28%) 44 (30%) 129 (30%)
Comparisons p-value
Active vs. placebo 0.539
i.v. vs. nebuliser 0.790
Overall, how satisfied are you with the service you received
Poor 4 (3%) 1 (1%) 1 (1%) 6 (1%)
Fair 8 (6%) 13 (9%) 6 (4%) 27 (6%)
Good 23 (17%) 19 (13%) 25 (17%) 67 (16%)
Very good 45 (33%) 54 (36%) 51 (35%) 150 (35%)
Excellent 57 (42%) 63 (42%) 62 (43%) 182 (42%)
Comparisons p-value
Active vs. placebo 0.645
i.v. vs. nebuliser 0.741
Values in brackets denote per cent of total.
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TABLE 35 Responses to the request for patients to guess their treatment
Response
Nebulised magnesium
sulphate (n = 332)
Intravenous magnesium
sulphate (n = 394)
Placebo
(n = 358)
Total
(n = 1084)
Number of responses 140 156 148 444
Believed they had received
magnesium sulphate
85 (61%)a 94 (60%)a 66 (45%)a 245 (55%)
How do you think magnesium sulphate was given?
Nebuliser 55 (39%)a 35 (22%) 28 (19%) 118 (27%)
i.v. 21 (15%) 40 (26%)a 28 (19%) 89 (20%)
Both 7 (5%) 13 (8%) 7 (5%) 27 (6%)
Do not know/not answered 2 (1%) 6 (4%) 3 (2%) 11 (2%)
NA 55 (39%) 62 (40%) 82 (55%) 199 (45%)
NA, not applicable.
a Correctly guessed.
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62Subgroup analysis
The protocol prespecified three key factors for subgroup analyses: age, baseline PEFR and previous receipt
of salbutamol. Table 36 shows the impact of these factors on the primary outcomes. In each case, the
factor (age, PEFR or previous receipt of salbutamol) was added to a model that also contained treatment
group and site. For change in VAS, the VAS at baseline was also included. Older age and lower PEFR at
baseline were both highly associated with an increase in admissions and also a greater reduction from
baseline in VAS. The latter is presumably a reflection of the greater severity (i.e. higher VAS at baseline)
among those with lower percentage PEFR. The use of salbutamol in the ED or ambulance prior to
randomisation was compromised by relatively small numbers without prior usage (n = 59), but those with
previous use were more likely to be admitted than those who had not (77% vs. 56%; p = 0.001).TABLE 36 Impact of age, PEFR at baseline and previous use of salbutamol on outcomes
Factor
Hospital admission Change in VAS (mm)
OR (95% CI) p-value
Mean difference
(95% CI) p-value
Age (per 10 year increase) 1.27 (1.13 to 1.43) < 0.001 2.3 (1.1 to 3.4) < 0.001
PEFR at baseline (per 10% of predicted increase) 0.81 (0.75 to 0.88) < 0.001 –1.4 (–2.2 to –0.6) 0.001
Previous use of salbutamol (yes vs. no) 2.83 (1.57 to 5.12) 0.001 –2.3 (–9.3 to 4.7) 0.520
The consistency of the treatment effect was assessed for each of the factors separately, specifically (a) age above or below
50 years; (b) baseline PEFR above the median value for the cohort (50%), below the BTS criteria for life-threatening asthma
(< 33%) or inbetween (33–50%): and (c) previous receipt of salbutamol in the ambulance or ED.
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between the nebulised and placebo arms, the graphical displays focus on the comparison of i.v. and
placebo. Figure 15 shows the ORs for admission to hospital for each subgroup and overall and, likewise,
Figure 16 shows the mean differences in VAS. The results appear consistent across all subgroups. The
subgroup of patients who had not previously received salbutamol appeared to have worse outcomes with
active treatment, but this analysis is limited by small numbers and wide CIs.Overall
Yes
No
< 50
Previously received salbutamol in ED or ambulance
Subgroup
  50
PEFR
33% to < 50%
   50%
Age (years)
< 33% 1.23 (0.42 to 3.62)
0.71 (0.51 to 1.00)
1.19 (0.37 to 3.84)
0.73 (0.51 to 1.05)
OR (95% CI)
0.66 (0.27 to 1.65)
0.69 (0.49 to 0.98)
0.67 (0.36 to 1.23)
0.67 (0.42 to 1.06)
Favours i.v. mg Favours placebo 
0.25 0.50 0.75 1.00 1.50 2.00 4.00
Odds ratio for hospital admission
>–
>–
FIGURE 15 Hospital admission, i.v. vs. placebo, by subgroup.
Overall
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> 50%
> 50
No
Subgroup
Previously received salbutamol in ED or ambulance
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difference (95% CI)
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– 3.6 (– 7.9 to 0.8)
– 2.2 (– 10.3 to 6.0)
– 2.1 (– 6.7 to 2.6)
– 2.9 (– 8.5 to 2.8)
– 7.2 (– 17.2 to 2.9)
5.0 (– 15.9 to 26.0)
Favours i.v. mg Favours placebo 
– 20.0 – 15.0 – 10.0 – 5.0 0.0 5.0 10.0
Mean change in VAS
FIGURE 16 Change in VAS by subgroup.
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RESULTS
64Economic analysis
Table 37 presents the results of the cost-effectiveness analysis of the QALY and cost data excluding
productivity costs. The placebo-treated population have the highest population mean QALY and there was
no apparent difference between the population mean QALYs associated with nebulised magnesium
sulphate and i.v. magnesium sulphate; there is a 67% chance that placebo is associated with the highest
population mean QALY. Nebulised magnesium sulphate has the highest population mean cost and
placebo has the lowest population mean cost; there is a 95% chance that placebo is associated with the
lowest population mean cost.
Figure 17 presents the cost-effectiveness frontiers for willingness to pay in the range £0 to £100,000.
There is a 97% and 96% chance that placebo has the highest net benefit at thresholds of £20,000 and
£30,000 respectively.
Table 38 presents the results of the cost-effectiveness analysis of the QALY and cost data, including
productivity costs. Nebulised magnesium sulphate has the highest population mean cost and placebo has
the lowest population mean cost; there is a 90% chance that placebo is associated with the lowest
population mean cost.TABLE 37 Quality-adjusted life-years: summary of cost-effectiveness analysis excluding productivity costs
Treatment
QALYs,
mean (SD)
Incremental
QALYs (95% CrI)
Cost, (£) mean
(SD)
Incremental cost,
£ (95% CrI) ICER
Placebo 0.063 (0.0030) – 1610 (89.7) –
Nebulised
magnesium
0.060 (0.0033) –0.011 to 0.006 1974 (115.3) 77 to 651 Dominated
i.v. magnesium 0.060 (0.0028) –0.011 to 0.005 1870 (110.8) –20 to 540 Dominated
CrI, credible interval; ICER, incremental cost-effectiveness ratio.
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FIGURE 17 Cost-effectiveness frontiers for willingness to pay, main QALY analysis.
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TABLE 38 QALYs: summary of cost-effectiveness analysis including productivity costs
Treatment
QALYs, mean
(SD)
Incremental
QALYs (95% CrI)
Cost (£),
mean (SD)
Incremental cost
(95% CrI) ICER
Placebo 0.063 (0.0030) – 2007 (107.4) –
Nebulised
magnesium sulphate
0.060 (0.0033) –0.011 to 0.006 2401 (120.9) 78 to 712 Dominated
i.v. magnesium
sulphate
0.060 (0.0028) –0.011 to 0.005 2219 (120.5) –104 to 530 Dominated
CrI, credible interval.
DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22Figure 18 presents the cost-effectiveness frontiers for willingness-to-pay in the range £0 to
£100,000. There is a 93% chance that placebo has the highest net benefit at thresholds of both
£20,000 and £30,000.
Table 39 presents the results of the cost-effectiveness analysis of the 2-hour breathlessness (change from
baseline) and cost data excluding productivity costs. Intravenous magnesium sulphate has the greatest
population mean change from baseline in 2-hour breathlessness, whereas nebulised magnesium sulphate
has the smallest population mean change from baseline in 2-hour breathlessness; there is a 97% chance
that i.v. magnesium sulphate is associated with the greatest population mean change from baseline 2-hour
breathlessness score.
Figure 19 presents the cost-effectiveness frontiers for willingness to pay in the range £0 to £1000. The
incremental cost-effectiveness ratio (ICER) for i.v. magnesium sulphate relative to placebo was £61.70/mm.
Table 40 presents the results of the cost-effectiveness analysis of the 2-hour breathlessness (change from
baseline) and cost data including productivity costs. Figure 20 presents the cost-effectiveness frontiers for
willingness to pay in the range of £0 to £1000. The ICER for i.v. magnesium sulphate relative to placebo
was £50.48/mm.0.0
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FIGURE 18 Cost-effectiveness frontiers for willingness to pay, QALY analysis including productivity costs.
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TABLE 39 Breathlessness: 2-hour change from baseline (VAS) – summary of cost-effectiveness analysis excluding
productivity costs
Treatment
Breathlessness
(VAS), mean (SD)
Incremental
breathlessness
(95% CrI)
Cost (£),
mean (SD)
Incremental Cost
(95% CrI) ICER
Placebo 29.5 (1.57) – 1610 (89.8) –
Nebulised magnesium
sulphate
27.8 (1.57) –6.0 to 2.7 1974 (115.3) 77 to 651 Dominated
i.v. magnesium
sulphate
33.7 (1.43) 0 to 8.4 1870 (110.9) –20 to 540 £61.7/mm
CrI, credible interval.
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FIGURE 19 Cost-effectiveness frontiers for willingness to pay, main breathlessness analysis.
TABLE 40 Breathlessness: 2-hour change from baseline (VAS) – summary of cost-effectiveness analysis including
productivity costs
Treatment
Breathlessness
(VAS), mean (SD)
Incremental
breathlessness
(95% CrI)
Mean cost,
£ (SD)
Incremental cost,
£ (95% CrI) ICER
Placebo 29.6 (1.57) – 2007 (107.4) –
Nebulised magnesium
sulphate
28.0 (1.57) –6.0 to 2.7 2401 (120.9) 78 to 712 Dominated
i.v. magnesium
sulphate
33.7 (1.43) 0.0 to 8.4 2219 (120.5) –104 to 530 £50.48/mm
CrI, credible interval.
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FIGURE 20 Cost-effectiveness frontiers for willingness to pay, breathlessness analysis including productivity costs.
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Overall, 81 (7%) participants required critical care and 157 (14%) required emergency medical
treatment (including critical care) within 7 days of initial attendance. Table 41 shows the criteria behind
these classifications.
Tables 42 and 43 show the results of univariate analysis. Table 42 shows the association between baseline
characteristics or categorised baseline physiological variables and each outcome. Table 43 shows the
p-values for the associations between fractional polynomials of continuous variables (as used in the model)
and for each outcome. There was some evidence that previous asthma admission, previous ITU admission,
other serious illness and percentage predicted PEFR, heart rate, respiratory rate, oxygen flow rate and VAS
breathlessness at baseline or after treatment were associated with unsuccessful treatment. Although
percentage predicted PEFR at presentation was associated with unsuccessful treatment it did not provide
very useful prognostic value (AUROC < 0.6).TABLE 41 Criteria for unsuccessful treatment
Criterion Number (%) of patients
Critical care 81 (7.5)
Emergency medical treatment 157 (14.5)
Reason
Stay on HDU or ICU 77 (7.1)
Arrhythmia 2 (0.2)
Emergency intubation 8 (0.7)
Non-invasive ventilation 7 (0.6)
Other event 4 (0.4)
Reattendance at ED/unscheduled inpatient reviewa 111 (10.2)
a Contributes to definition 2 only.
The total numbers do not add up to ‘overall’ as some patients had more than one reason.
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TABLE 42 Association between baseline characteristics or categorised baseline physiological variables and
each outcome
Factor Requiring critical care
Requiring emergency
medical treatment
Overall 81 (7%) 157 (14%)
Age group (years) (p = 0.921) (p = 0.722)
16–24 21 (8%) 43 (15%)
25–34 20 (7%) 42 (16%)
35–44 16 (7%) 27 (12%)
45–54 13 (7%) 26 (14%)
55–64 7 (9%) 13 (17%)
65+ 4 (11%) 6 (17%)
Sex (p = 0.798) (p = 0.396)
Female 56 (7%) 115 (15%)
Male 25 (8%) 42 (13%)
Ethnic category (p = 0.121) (p = 0.180)a
White 77 (8%) 140 (14%)
Mixed 2 (25%) 4 (50%)
Asian or Asian British 0 (0%) 6 (16%)
Black or black British 0 (0%) 1 (9%)
Other 0 (0%) 0 (0%)
Not stated 2 (4%) 6 (12%)
Smoker (p = 0.639) (p = 0.822)
Never 31 (7%) 63 (14%)
Current 28 (8%) 54 (15%)
Previous 22 (9%) 39 (16%)
Missing 0 (0%) 1 (4%)
Previous asthma admission (p = 0.061) (p = 0.034)
No 21 (5%) 44 (11%)
Yes 60 (9%) 113 (16%)
Previous ITU asthma admission (p = 0.002) (p = 0.070)
No 60 (6%) 127 (14%)
Yes 21 (13%) 30 (19%)
Previous serious lung disease (p = 0.348) (p = 0.719)
No 75 (8%) 142 (15%)
Yes 5 (5%) 13 (13%)
Missing 1 (7%) 2 (14%)
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TABLE 42 Association between baseline characteristics or categorised baseline physiological variables and
each outcome (continued )
Factor Requiring critical care
Requiring emergency
medical treatment
Other serious illness (p = 0.002) (p = 0.001)
No 55 (6%) 111 (13%)
Yes 26 (13%) 44 (22%)
Missing 0 (0%) 2 (17%)
% of predicted PEFR at baseline (p = 0.153) (p = 0.042)
≤ 35 22 (10%) 42 (20%)
> 35–45 13 (6%) 27 (13%)
> 45–54 13 (7%) 24 (12%)
> 54–67 11 (6%) 26 (14%)
> 67 9 (4%) 20 (10%)
Missing 13 (18%) 18 (24%)
Pulse at baseline (beats per minute) (p < 0.001) (p < 0.001)
≤ 95 6 (3%) 26 (11%)
95–107 15 (7%) 22 (11%)
107–115 18 (9%) 31 (16%)
115–125 11 (5%) 23 (11%)
> 125 31 (14%) 55 (25%)
Missing 0 (0%) 0 (0%)
Respiratory rate at baseline (breaths per minute) (p < 0.001) (p < 0.001)
≤ 20 10 (4%) 31 (11%)
> 20–23 12 (8%) 21 (14%)
> 23–26 20 (8%) 29 (11%)
> 26–30 11 (5%) 27 (13%)
> 30 28 (15%) 49 (26%)
Missing 0 (0%) 0 (0%)
Systolic BP at baseline (mmHg) (p = 0.220) (p = 0.634)
≤ 114 14 (7%) 31 (15%)
> 114–125 12 (5%) 27 (11%)
> 125–135 16 (7%) 35 (16%)
> 135–147 16 (8%) 30 (15%)
> 147 23 (11%) 34 (16%)
Missing 0 (0%) 0 (0%)
continued
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TABLE 42 Association between baseline characteristics or categorised baseline physiological variables and
each outcome (continued )
Factor Requiring critical care
Requiring emergency
medical treatment
Diastolic BP at baseline (mmHg) (p = 0.238) (p = 0.192)
≤ 63 17 (7%) 30 (13%)
> 63–70 13 (7%) 32 (16%)
> 70–78 11 (5%) 23 (10%)
> 78–86 17 (8%) 34 (16%)
> 86 23 (11%) 38 (18%)
Missing 0 (0%) 0 (0%)
Oxygen flow at baseline (l/minute) (p = 0.027) (p = 0.054)
0 11 (4%) 34 (13%)
1–5 15 (9%) 26 (15%)
6 38 (10%) 62 (16%)
7–10 10 (6%) 21 (12%)
≥ 10 7 (14%) 14 (29%)
Missing 0 (0%) 0 (0%)
BP, blood pressure.
a p-value from Fisher’s exact test.
p-values from chi-squared test unless stated otherwise.
Physiology factors were modelled as non-linear terms in the logistic regression model, but for ease of display are presented
here in quintiles.
TABLE 43 p-values for associations between baseline or post-treatment physiology measures and outcome
Variable
Requiring critical care Requiring emergency medical treatment
Baseline Post treatment Baseline Post treatment
Heart rate < 0.001 < 0.001 < 0.001 < 0.001
Respiratory rate < 0.001 < 0.001 < 0.001 < 0.001
Systolic BP 0.074 0.211 0.390 0.604
Diastolic BP 0.164 0.420 0.086 0.819
Oxygen saturation (on oxygen) 0.428 0.001 0.333 0.001
Oxygen saturation (on air) 0.549 0.945 0.283 0.272
Oxygen flow rate 0.009 < 0.001 0.041 < 0.001
VAS breathlessness 0.028 < 0.001 0.003 < 0.001
% predicted PEFR 0.008 < 0.001 0.012 < 0.001
BP, blood pressure.
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DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22Tables 44 and 45 show the results of multivariate analysis for prediction of need for critical care and need
for any emergency medical treatment respectively. The effect of PEFR on hospitalisation remained similar in
the three models and with both outcomes, but the addition of physiological features and the presence of
serious comorbidity improved prognostic ability. The presence of other serious illness, raised heart rate and
raised oxygen flow requirement were all associated with increased need for critical care. Change in
physiology measures over the 2-hour observation period increased the predictive ability of the model
further, with a decrease in heart rate or increase in PEFR predicting reduced need for critical care. The
derived model was robust and produced comparable fits to the subgroups (temporal, season and teaching/
non-teaching hospital). Nonetheless, the resultant model had limited predictive ability (model incorporating
change in physiology: AUROC = 0.77), suggesting that there is limited means to predict events for
individual patients.
A similar theme emerged from the analysis of prediction of need for any medical treatment, although
more terms were identified. There was a quadratic relationship between pretreatment heart rate and
needing emergency medical treatment, with the outcome being least likely when the heart rate was in the
range 90–100 beats per minute. In addition, pretreatment respiratory rate was significantly associated with
the need for emergency medical treatment (higher rate meaning a greater probability of the outcome).
The derived model incorporating 2-hour change in physiology was robust and comparable in the
subgroups, but again predictive ability remained low (AUROC = 0.69).TABLE 44 Prediction of need for critical care
Factor
Model 1
(pretreatment PEFR)
Model 2
(pretreatment
characteristics
and physiology)
Model 3
(pretreatment
characteristics
and physiology, and
2-hour changes in
physiology)
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Number of patients with
data
1010 999 956
PEFR (% of predicted)a 0.82 (0.72 to 0.95) 0.007 0.82 (0.71 to 0.95) 0.008 0.83 (0.71 to 0.97) 0.017
Other serious illness 2.15 (1.24 to 3.73) 0.006 2.04 (1.12 to 3.70) 0.019
Heart rate (beats
per minute)a
1.27 (1.12 to 1.45) < 0.001 1.45 (1.23 to 1.70) < 0.001
Oxygen flow (l/minute)a 2.08 (1.08 to 4.00) 0.028 2.11 (0.99 to 4.49) 0.054
Change in PEFR (% of
predicted)a
0.77 (0.63 to 0.95) 0.015
Change in pulse (beats
per minute)a
1.70 (1.35 to 2.12) < 0.001
Model AUROC 0.60 0.70 0.77
a The ORs for physiological variables are presented per 10-unit increase.
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TABLE 45 Prediction of need for emergency medical treatment
Factor
Model 1
(pretreatment PEFR)
Model 2
(pretreatment
characteristics
and physiology)
Model 3
(pretreatment
characteristics
and physiology, and 2-hour
changes in physiology)
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Number of patients with
data
1010 997 954
PEFR (% of predicted)a 0.87 (0.79 to 0.96) 0.008 0.88 (0.79 to 0.97) 0.010 0.87 (0.78 to 0.97) 0.010
Other serious illness 1.77 (1.16 to 2.71) 0.009 1.67 (1.07 to 2.61) 0.023
Heart rate (beats
per minute)a
< 0.001 < 0.001
Linear term 0.48 (0.25 to 0.95) 0.57 (0.28 to 1.17)
Quadratic term 1.04 (1.01 to 1.07) 1.03 (1.00 to 1.07)
Respiratory rate (breaths
per minute)a
1.34 (1.03 to 1.76) 0.032 1.42 (1.06 to 1.88) 0.017
Change in PEFR (% of
predicted)a
0.82 (0.71 to 0.93) 0.003
Change in pulse (beats
per minute)a
1.30 (1.12 to 1.52) 0.001
Model AUROC 0.57 0.64 0.69
a The ORs for physiological variables are presented per 10-unit increase.
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DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22Chapter 4 DiscussionMain findingsAnalysis of this three-arm trial involved two preplanned contrasts: (1) active treatment (i.v. and nebulised
magnesium sulphate combined) compared with placebo and (2) i.v. compared with nebulised magnesium
sulphate. This was based on a systematic review and meta-analysis of previous trials of magnesium
sulphate in adults,11 which suggested that both i.v. and nebulised magnesium sulphate had a potential
effect on respiratory function and hospital admission but found no direct comparisons between i.v. and
nebulised magnesium sulphate. We found no evidence that active treatment was more effective than
placebo, but we did find some evidence that active treatment was associated with a slightly higher risk of
side effects [15.6% vs. 10.1%, OR 1.68 (95% CI 1.11 to 2.52; p = 0.014)].
Our choice of preplanned comparisons could be criticised if it was thought that one mode of
administration was superior to the other, especially if the inferior mode of administration was associated
with worse outcomes than placebo. We therefore reported comparisons between i.v. treatment and
placebo, and between nebulised treatment and placebo, although it should be recognised that these
comparisons were not those originally specified. We found no evidence that nebulised magnesium
sulphate was more effective than placebo. In fact, any non-significant trends in the outcomes tended to
favour placebo. The only significant effect of nebulised magnesium sulphate compared with placebo was a
small increase in the risk of side effects [15.7% vs. 10.1%, OR 1.67 (95% CI 1.05 to 2.66; p = 0.031)].
Intravenous magnesium sulphate was associated with a lower rate of hospital admission than placebo, but
the difference was not significant [OR 0.73 (95% CI 0.51 to 1.04, p = 0.083)], and there was no evidence
of an effect on VAS breathlessness [mean difference 2.6 mm (95% CI –1.6 to 6.8 mm; p = 0.231)]
compared with placebo. Although i.v. magnesium sulphate appeared superior to nebulised magnesium
sulphate [mean difference = 5.1 mm, (95% CI 0.8 to 9.4 mm)], the magnitude of the difference in clinical
terms is small when considered in the context of a minimum clinically significant difference for VAS
breathlessness of 22mm.48 There was also no evidence of any clinically worthwhile effect from i.v.
magnesium sulphate compared with placebo on secondary outcome measures, including change in PEFR
[2.4 l/minute (95% CI –8.8 to 13.6 l/minute; p = 0.680)]. Overall, therefore, we were unable to
demonstrate a clinically worthwhile benefit from i.v. magnesium sulphate.
Given the failure to demonstrate clinical effectiveness of magnesium sulphate it is not surprising that the
economic analysis showed a corresponding lack of cost-effectiveness, with high probabilities that placebo is
associated with the highest net benefit at conventionally used thresholds for willingness to pay on the cost
per QALY analysis. The analysis of incremental cost per unit change in VAS breathlessness is more difficult
to interpret as it showed that i.v. magnesium sulphate could provide a non-significant improvement in
outcome at a higher cost, compared with placebo. The ICER was around £50–£60/mm improvement in
VAS, but both cost and effectiveness estimates were surrounded by considerable uncertainty.
Our additional analysis to explore the predictive value of baseline characteristics and response to treatment
showed that the percentage predicted PEFR at baseline predicted the need for critical care or emergency
medical treatment, but that the predictive value was limited (AUROC 0.60 and 0.57 respectively). The
presence of other serious illnesses, heart rate, the oxygen flow rate required, change in the percentage
predicted PEFR and change in heart rate all predicted the need for critical care, and a predictive model
based on these variables had a reasonable predictive value (AUROC 0.77). The presence of other serious
illnesses, increased heart rate, increased respiratory rate, change in the percentage predicted PEFR and
change in heart rate all predicted the need for emergency medical treatment within the next week
(including critical care), but a predictive model based on these variables had only a limited predictive value
(AUROC 0.69).73
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DISCUSSION
74Current BTS/SIGN guidance2 uses PEFR and a number of other parameters to guide hospital admission
decisions, but does not recommend the use of any decision rule or predictive model. Our findings confirm
that PEFR is a useful, albeit limited, predictor of adverse outcome. Taking the heart rate, other serious
illnesses and the required oxygen flow rate into account could improve prediction, but the predictive
model based on these values was unlikely to be adequate for guiding practice. This was a secondary
analysis, however, and the sample size was determined by the trial and recruitment constraints. A larger
number of outcomes would be required to analyse the predictor variables with sufficient statistical power
to ensure an optimal model.Comparison with previous trialsThe most recent meta-analysis of magnesium sulphate for acute asthma11 showed some heterogeneity
among existing trials, but concluded that overall there was uncertain evidence suggesting that both i.v.
and nebulised magnesium sulphate could have a clinically worthwhile effect on respiratory function and
admission to hospital. It is not unusual for the results of meta-analyses of small trials to be negated or
even overturned in large scale, robust trials and there are a number of potential reasons why the findings
of the 3Mg trial and the meta-analysis are inconsistent. Meta-analyses may be subject to publication bias if
positive trials are preferentially submitted and accepted for publication, and some previous trials may have
been limited by inadequate allocation concealment or blinding that inflated estimates of treatment effects.
All three arms of the 3Mg trial received treatment with nebulised beta-agonists, ipratropium bromide and
corticosteroids in accordance with BTS/SIGN guidance,2 which may have limited the potential for
magnesium sulphate to provide additional bronchodilatation, whereas it was not always clear that all
patients received optimal standard treatment in previous trials. It is worth noting that patients in the
placebo arm showed marked improvements in PEFR and VAS breathlessness, and few required respiratory
support, indicating a good response to standard treatment alone.
One potential explanation that can probably be discounted is that the trial treatment was inadequate in
the 3Mg trial. The protocol specified doses of i.v. and nebulised magnesium sulphate that were at the top
end of those used in previous trials. Data presented in the supplemental tables show high adherence to
the trial protocol, with most patients receiving the full dose of the relevant drugs. Pragmatic trials carry an
inevitable risk that trial treatment will be delivered in a suboptimal manner, but we found no significant
evidence of this in the 3Mg trial.Strengths and weaknessesThe 3Mg trial was designed as a pragmatic trial to determine the effectiveness of using magnesium
sulphate alongside other treatments as part of routine ED practice. As such it can tell us whether or not
magnesium sulphate is an effective treatment for typical patients presenting to the ED with acute severe
asthma. However, it cannot tell us whether magnesium sulphate may have benefits in a more narrowly
defined patient population or a more specialised setting. The study population was pragmatically defined
using information routinely available to ED staff. This means that the findings are generalisable to typical
patients attending hospital with acute asthma, but also means that the study population could have
included some patients with other diagnoses. In particular, the study population included a proportion of
older patients and those who had smoked for a number of years in whom a diagnosis of chronic
obstructive pulmonary disease may be more likely than asthma. We evaluated magnesium sulphate in
combination with standard treatment rather than assessing it alone. This may have reduced the potential
for magnesium sulphate to make a difference, but withholding standard treatment would have been
unethical and would not have reflected typical practice. We selected primary outcomes that measured the
effect of treatment on symptoms (VAS breathlessness) and clinical management (hospital admission).
We also measured physiological parameters and PEFR as secondary outcomes. It is possible that otherNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22measures, such as FEV1, might have been more sensitive to changes in respiratory function, but these are
not usually measured in the ED and are of uncertain clinical relevance.
We deliberately excluded patients with life-threatening asthma and were unable to power the study
to detect differences in serious adverse outcomes (including death), therefore we are unable to
determine whether or not magnesium sulphate may have an effect on serious adverse outcomes in
life-threatening asthma.
Although 3Mg is the largest trial undertaken of magnesium sulphate in acute asthma it is still possible that
i.v. magnesium sulphate has a modest effect on admission to hospital that was not proven in this trial.
Some of the differences in outcome between i.v. magnesium sulphate and placebo showed trends
towards benefit, most notably hospital admission, and the CI includes the possibility of a worthwhile effect
(albeit also including the possibility of no effect or even a slightly increased admission rate). The
recruitment rate was slower than expected and this meant that, despite additional funding, increasing the
number of recruiting centres and prolonging recruitment, we fell short of our recruitment target of 1200
participants. This reduced the power of the trial from 90% to 87% to detect a 10% difference in
admission rate. The effect on the power to detect other outcomes was minimal. The sample size was
mainly determined by the primary health service outcome, so the trial was powered to detect an 8-mm
change in VAS breathlessness despite the minimum clinically significant difference being estimated to be
22mm. We also assumed a conservative attrition rate of 20% for VAS breathlessness, whereas it was
actually only 10% and, therefore, power to detect differences in VAS breathlessness was maintained.
The trial was double blinded to reduce the potential for placebo effects and measurement bias. The
responses to the questionnaire suggested that more patients in the active treatment arms than in
the placebo arm thought that they had received active treatment, suggesting that blinding did not
completely overcome the patient’s ability to detect that they had received active treatment. However,
given the overall negative findings and pragmatic nature of the trial, this does not seem to be an
important source of bias.
Although the attrition rates for the primary outcomes and physiological secondary outcomes were low, the
response rate to the questionnaire was lower than anticipated. Previous trials in ED patients have achieved
response rates of around 70%,69,70 but our response rate was 40%. The reasons for this are not clear but
may reflect a younger age group, general population disengagement with traditional mailing over time or
recognised associations between presentation with asthma at the ED and lower willingness to engage with
health care. The low response rate means that the findings of the EQ-5D analysis, health-care resource use
survey and patient satisfaction survey should be treated with caution. However, the lack of evidence of
clinical effectiveness demonstrated in the primary outcomes and physiological secondary outcomes
undermines the potential mechanism for changes in the questionnaire outcomes, while the lack of any
important differences between the trial groups means that there is little to be gained from speculating
about the potential effect of responder bias.75
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DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22Chapter 5 ConclusionsImplications for health careThe findings of this trial suggest that there is no role for nebulised magnesium sulphate in the
management of acute severe asthma in adults and only a limited potential role for i.v. magnesium
sulphate. Patients receiving placebo alongside standard treatment showed marked improvements in
breathlessness and PEFR, and few required respiratory support. Although most were admitted to hospital,
we found no evidence that nebulised magnesium sulphate reduced the admission rate and the effect on
admission rates from i.v. magnesium sulphate was not significant. The low rate of side effects and adverse
events (other than those related to the underlying illness) suggests a low risk of harm from i.v. magnesium
sulphate administration, but the corresponding evidence of benefit is modest and uncertain.
The findings of the trial do not apply to patients with life-threatening asthma, who were excluded from
the trial. The low rate of adverse events associated with i.v. magnesium sulphate treatment may reassure
clinicians who feel that in life-threatening asthma any weak evidence of benefit extrapolated from this trial
or other sources provides a justification for administering i.v. magnesium sulphate. However, given the
failure to demonstrate evidence of benefit, it is important to ensure that magnesium sulphate is not used
as an alternative to effective treatments or as a way of delaying the provision of respiratory support.
The BTS/SIGN guidelines2 do not currently recommend routine use of i.v. or nebulised magnesium sulphate
in the management of acute severe asthma, but recommend considering a single dose of i.v. magnesium
sulphate (following consultation with senior medical staff) for patients with severe acute asthma who have
not had a good initial response to inhaled bronchodilator therapy or patients with life-threatening or near
fatal asthma. Our findings do not suggest any reliable expectation of clinical benefit from i.v. or nebulised
magnesium sulphate.
The BTS/SIGN guidance recommends using PEFR to guide decision-making in acute asthma. Our secondary
analysis suggests that PEFR predicts adverse outcome. Heart rate, other serious illnesses and the required
oxygen flow rate could also be used to predict adverse outcome, but the predictive value of a model based
on these parameters is not high.Recommendations for researchFurther clinical trials of magnesium sulphate in adults with acute asthma are very unlikely to be
worthwhile. It is possible that i.v. treatment could have a modest effect on admission to hospital that was
not detected by 3Mg, but a much larger trial would be needed to detect this. Despite having extensive
experience of undertaking trials in the emergency setting, an excellent network of supporting hospitals
and a simple, pragmatic trial protocol we failed to achieve our recruitment targets and took longer to
complete the trial than expected. Undertaking a larger trial to obtain a more precise estimate of treatment
effect would therefore require international collaboration and incur substantial costs. It is very unlikely that
this could be justified given the low probability of detecting a worthwhile benefit.
The results of the 3Mg trial show that, although standard treatment for acute severe asthma produces
marked improvements in breathlessness and PEFR, with a low rate of adverse outcome or requirement for
respiratory support, most patients were admitted to hospital after ED treatment. This suggests there is still
scope for new treatments or other changes in clinical practice, to improve the management of acute
severe asthma.77
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DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22Appendix 2 Brief information sheetInitial patient information sheet for the 3Mg study(Is magnesium sulphate, in addition to standard treatment, effective in patients with an asthma attack?)
You are being invited to take part in a research study. The purpose of the study is to find out whether
treating an asthma attack with magnesium sulphate, in addition to standard treatment, relieves symptoms
of breathlessness and reduces the chances that people with acute asthma will need to be admitted to
hospital. The study will compare standard treatment for asthma to standard treatment and magnesium
sulphate, given either into a vein or through a nebuliser.Why have I been chosen?
You have come to hospital with an asthma attack. The doctors treating you think that magnesium
sulphate, if it is effective, may ease your symptoms of breathlessness and improve your chances of
avoiding hospital admission.Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you will be asked to sign a consent
form. You will be free to withdraw at any time, without giving a reason. A decision to withdraw at any
time or a decision not to take part, will not affect the standard of care you receive.What will happen to me if I take part?
If you agree to take part you will be given the standard treatment for asthma. You will also be given an
infusion into a vein in your arm and three nebulisers. Along with the standard treatments you will be given
one of the following three alternatives:
l magnesium sulphate added to the nebuliser but not the infusion
l magnesium sulphate added to the infusion but not the nebuliser
l nothing added to either the infusion or the nebuliser (just standard treatment).
We will then monitor your symptoms for up to 4 hours, after which the doctor will advise whether you
should be admitted to hospital or go home. Neither you, nor the doctors will know which treatment you
have been given.What do I have to do?
All the treatments will be given by the doctors and nurses. You will to need answer some questions and
do a Peak Flow recording (breathing test).Are there any side effects to treatment?
Magnesium sulphate can cause feelings of nausea, vomiting, thirst or facial flushing, particularly when
given through a vein. In rare cases overdose of magnesium sulphate can cause weakness, coma or heart
problems. The doctors will monitor your heartbeat during treatment.
We will give you more information shortly, when you are feeling better.
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PATIENT INFORMATION SHEET FOR THE 3Mg STUDY(Is magnesium sulphate, in addition to standard treatment, effective in patients with an asthma attack?)
You are being invited to take part in a research study that is organised by the University of Sheffield and
undertaken at XXX Hospital. Before you decide it is important for you to understand why the research is
being done and what it will involve. Please read the following information carefully. Ask us if there is
anything that is not clear or if you would like more information.What is the purpose of the study?
The purpose of the study is to find out whether treating an asthma attack with magnesium sulphate
relieves symptoms of breathlessness and reduces the chances that people with acute asthma will need to
be admitted to hospital.
Magnesium sulphate has been used to treat asthma attacks for several years. It can be given either as an
infusion into a vein or by being inhaled using a nebuliser. We know that treatment with magnesium
sulphate can improve the results of breathing tests, but we do not yet know whether it improves patient’s
symptoms of breathlessness or reduces their chances of needing hospital admission. We also do not know
whether it works better by infusion into a vein or inhaled through a nebuliser.
The study will compare standard treatment for asthma, with the addition of magnesium sulphate (given
either into a vein or through a nebuliser), to standard treatment without magnesium sulphate.Why have I been chosen?
You have come to hospital with an asthma attack. The doctors treating you think that magnesium
sulphate, if it is effective, may ease your symptoms of breathlessness and improve your chances of
avoiding hospital admission.Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you will be given this information
sheet to keep and be asked to sign a consent form. You are still free to withdraw at any time and without
giving a reason. A decision to withdraw at any time, or a decision not to take part, will not affect the
standard of care you receive.What will happen to me if I take part?
If you agree to take part you will be given standard treatment for asthma with oxygen, nebulisers and
steroids (prednisolone or hydrocortisone). In addition you will also be given an infusion of saline (salt and
water) into a vein in your arm. Along with the standard treatments you will be given one of the following
three alternatives:
l magnesium sulphate added to the nebuliser but not the infusion
l magnesium sulphate added to the infusion but not the nebuliser
l nothing added to either the infusion or the nebuliser (i.e. just standard treatment on its own).
After you have been given the treatment we will monitor your symptoms for up to 4 hours. Depending
upon your response to treatment the doctor will then advise whether you should be admitted to hospital
or go home.91
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92One month from now we will examine all of your hospital records and then send you a questionnaire in
the post or telephone you asking you about your health, your recent use of health services and what you
thought about the care you received.
You will be put into one of the three treatment groups by chance (randomly). Neither you, the staff nor
the researchers will know which treatment you have been given (this is known as a ‘blind trial’). At the
end of the trial the researchers will compare patients in the three groups and then reveal which treatment
was which to find out which treatment helped patients most.
If it may affect your care then the doctors treating you can find out which treatment you have been given.What do I have to do?
All the treatments will be given by the doctors and nurses. You will to need answer some questions and
do a peak flow recording (breathing test) to monitor your progress, and then complete a questionnaire in
1 month’s time.Are there any side effects to treatment?
Magnesium sulphate can cause feelings of nausea, vomiting, thirst or facial flushing, particularly when
given through a vein. In rare cases overdose of magnesium sulphate can cause weakness, coma or heart
problems. The doctors will monitor your heartbeat during treatment.What are the possible benefits of taking part?
We cannot promise that the study will help you but doing the study may help to improve the treatment of
people with an asthma attack.What if there is a problem?
If you have a concern about any aspect of this study, you should ask to speak with the researchers who
will do their best to answer your questions (contact details below). If you remain unhappy and wish to
complain formally, you can do this through the NHS Complaints Procedure. Details can be obtained from
the hospital.
In the event that something does go wrong and you are harmed during the research study there are no
special compensation arrangements. If you are harmed and this is due to someone’s negligence then you
may have grounds for a legal action for compensation against the University of Sheffield or XXX Hospital
but you may have to pay your legal costs. The normal National Health Service complaints mechanisms will
still be available to you.Will my taking part in the study be kept confidential?
We will inform your GP that you have taken part in this study. We will record information about your
treatment over the next few hours and a member of the research team will record information from your
hospital notes and computer records in 1 month’s time. All information that is collected about you during
the course of this study will be kept strictly confidential. The information will be stored in a secure area of
the hospital. A copy of the information will be sent to the University of Sheffield where it will be stored in
a secure area and also kept as a password-protected computer file, both of which can only be accessed by
the research team and regulatory authorities. We will destroy all identifiable information 5 years after the
end of the study. An anonymised copy of the computer file (with any details that might identify you
removed) will be retained and made available to other researchers for use in future studies.What will happen if I don’t want to carry on with the study?
You can withdraw from the study at any time. We will need to keep the information you have given up to
the time you withdraw but will not collect any new information or send you the questionnaire.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18220 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 22What will happen to the results of the research study?
We will publish the results in a scientific journal and produce a report that is freely available to anyone
who wishes to read it. You will not be personally identified in any report or publication we produce.
Please contact us using the details below if you would like to see a summary of the results when the
trial is completed.Who is organising and funding the research?
The research is organised by the University of Sheffield and funded by the Department of Health.Who has reviewed the study?
This study was given a favourable ethical opinion for conduct in the NHS by the Scotland A Research
Ethics Committee.
Further information can be obtained from: Prof SW Goodacre
Medical Care Research Unit
University of Sheffield
Regent Court, 30 Regent Street
Sheffield S1 4DA
0114 222 0842, s.goodacre@sheffield.ac.uk
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